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ABSTRACT 
Modulation of gene expression and DNA adduct formation by 
chlorophyllin in human mammary cells exposed to benzopyrenes 
 
    Kaarthik John 
 
 
This study investigated metabolic activation by benzopyrenes (BP and B[e]P) in 
human mammary cells and modulation by chlorophyllin (CHL, a chemopreventive agent). 
Among 6 NHMEC strains monitored using microarrays, 54 genes were up-regulated and 11 
down-regulated by signal log ratio (SLR) ≥ 1.5 on treatment with BP alone. Pre CHL + 
post BP+CHL treatment up-regulated the expression of 129 genes and down-regulated 
those of 35 genes by SLR ≥ 1.5. Studies on CYP1 gene induction and BP-DNA adduct 
formation among 20 NHMECs revealed wide inter-individual variations both in the 
induction (3-96-fold for CYP1A1 and 4-43-fold for CYP1B1, respectively) and modulation 
(2-54-fold and 1-39-fold for CYP1A1 and CYP1B1, respectively) of CYP1 gene expression 
and reduction of BP-DNA adduct formation (0% to 86%) on treatment with BP±CHL. 
B[e]P was a very poor inducer of CYP1 gene expression and also exhibited no detectable 
adduct formation among the 2 NHMEC strains used, when compared to BP. There was a 
reduction of BP induced CY1A1 (0-40% among the 2 cell strains) and CYP1B1 expression 
(5-50% among the 2 cell strains) across all CHL treatments except for pre CHL+ post BP 
treatment and pre CHL + post BP+CHL treatment in one of the cell strains. CHL enhanced 
B[e]P induced CYP1 gene expression on treatment of cells with B[e]P + CHL and pre CHL 
+  post B[e]P + CHL. When MCF-7 cells were compared to NHMECs, though basal 
CYP1B1 expression was nearly 348 times that of CYP1A1, MCF-7 cells exhibited highly 
inducible CYP1A1 expression (114 fold) compared to CYP1B1 expression (5 fold). None of 
the different CHL treatments modulated CYP1 gene expression or BP-DNA adduct 
formation in MCF-7 cells as opposed to NHMECs. When MCF-7 cells were compared to 
M00012, a NHMEC, across a range of CHL concentrations, only 3μM, 4μM and 16μM 
CHL mitigated CYP1 expression to different extents. BP-DNA adduct levels were 
unaltered in MCF-7 cells but reduced in concentration dependent manner in M00012. 
These studies show the wide inter-individual variability in response to carcinogens and 
chemopreventive agents which are to be accounted for while designing intervention 
strategies. 
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1.0 INTRODUCTION 
 
Human exposures to various compounds such as polycyclic aromatic hydrocarbons 
(PAHs), halogenated hydrocarbons (HHs), aromatic amines (AAs), microbial toxins, drugs 
and other xenobiotic compounds occur through diet, occupation, medicines and/or 
environment. Benzo(a)pyrene (BP) is a PAH found in tobacco smoke, vehicle exhaust, 
indoor heating and various industrial processes, and it is a ubiquitous environmental pollutant 
and potent procarcinogen  (IARC 1987; Osborne et al. 1987). On entering the body it can 
follow a number of routes some of which lead to its bioactivation or detoxication. 
Metabolic activation of PAHs (e.g., BP) is necessary for them to exert their adverse 
biological and carcinogenic effects, and cytochrome P450 metabolism is a key factor in this 
process. Cytochrome P450s (CYPs) constitute a superfamily of heme thiolate proteins, that 
are likely the most important classes of enzymes involved in the metabolism of all 
xenobiotics (Guengerich 2001). Through their action, together with other enzymes (epoxide 
hydrolases) the bioactivation of BP proceeds, leading to the generation of highly reactive 
electrophiles capable of damaging cellular macromolecules such as DNA, RNA and protein 
(Weston et al. 2005). In addition, CYP450s have a normal role in hormone metabolism, and 
since BP acts to generally induce the activity of a range of CYP450s through activation of the 
aryl hydrocarbon receptor, BP and other PAHs may be a significant factor in hormonal 
carcinogenesis   
BP, by acting as a ligand for the AhR, enters the cell and induces CYP genes (Oesch-
Bartlomowicz et al. 2005). CYP1A1, CYP1B1 and CYP3A4 are the predominant CYP 
isoforms documented to be involved in the metabolism of BP. The predominant pathway of 
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metabolism involves the initial oxidation of BP by CYP1A1/CYP1B1 at the 7, 8 position 
followed by hydrolysis by epoxide hydrolase to dihydrodiols and then further oxidation at the 
9, 10 olefinic bond to yield dihydrodiol epoxides, which being highly electrophilic bind 
covalently to DNA leading to genetic damage (Weston et al. 2005). CYP1A1 and CYP1B1 
are also potent steroid hydroxylases with CYP1B1 being a potent estradiol 4 hydroxylase. 4-
OHE2 has been shown to possess a strong cell proliferative effect in various estrogen 
responsive tissues such as those of the breast and the endometrium and is thereby implicated 
in their carcinogenesis (Cavalieri et al. 2002). 
Given the ubiquitous nature of BP, a complete avoidance of exposure may be 
difficult. Chemopreventive agents that block or even reverse the carcinogenic process may 
therefore be a useful alternative consideration. CHL, a water soluble sodium-copper or 
potassium-copper metalloporphyrin has been shown to exhibit anti-carcinogenic, anti-
mutagenic, anti-tumorigenic and anti-oxidant properties in various studies and model systems 
(Sarkar et al. 1994; Tachino et al. 1994; Dashwood 1997a; Reddy et al. 1999; Kamat et al. 
2000). It has also been used as a safe and effective intervention strategy in various 
developing parts of Africa and China with populations at high risk for developing 
hepatocarcinoma (HCC) due to the regular consumption of aflatoxin contaminated foods 
(Kensler et al. 2004). 
Due to its carcinogenic properties, BP has been a compound of intense research 
interest since its isolation in the 1930s. However, very few studies have been conducted on 
the effect of BP on genome wide gene expression patterns, effect of intervention agents on 
modulating these expression patterns on a genomic scale and in turn the effects of this 
modulation to the individual in question. In addition, malignantly transformed cells are often 
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used as alternatives to normal cells in in vitro studies due to their ease in maintenance and the 
assumption of their similarity to normal cells in response to carcinogenic stress. However, 
whether or not malignantly transformed cells are appropriate models to use in studies of 
metabolic activation and chemical carcinogenesis is an important question to consider. 
This dissertation considers the metabolism and activation of an important, 
carcinogenic polycyclic aromatic hydrocarbon to which everyone is exposed. It further 
considers inter-individual variation in certain metabolic factors that impact an individual’s 
risk of cancer, and it examines the extent to which these factors may be mitigated by the 
introduction of a chemical intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4
 
Objectives 
The goals and objectives of these studies were to: 
 
• Assess genome-wide changes in gene expression patterns among a panel of 6 normal 
human mammary epithelial cells (NHMECs) on exposure to BP in the absence or 
presence of CHL in order to seek biomarkers for chemopreventive intervention. 
•  Determine the extent of inter-individual variation in CYP1A1 and CYP1B1 gene 
expression among a larger panel of 20 NHMECs on exposure to BP in the absence or 
presence of CHL. 
•  Determine the extent of inter-individual variation in BP-DNA adduct formation 
among a larger panel of 20 NHMECs on exposure to BP in the absence or presence of 
CHL. 
• Examine BP and B[e]P in parallel for their effect on CYP1A1 and CYP1B1 gene 
expression and DNA adduct formation in 2 NHMECs in the absence or presence of 
CHL. 
• Examine NHMEC(s) in parallel with a cancerous cell line, MCF-7 for their effect on 
CYP1A1 and CYP1B1 gene expression and DNA adduct formation on exposure to BP 
in the absence or presence of CHL. 
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2.0 REVIEW OF LITERATURE 
 
2.1 Introduction 
 
Cancer is the second largest cause of mortality next only to cardiovascular diseases. 
Nearly 1.4 million new cancer cases (excluding noninvasive cancer) are expected to be 
diagnosed in the US in 2006 and more than 500,000 will die (http://www.cancer.org). A large 
proportion of these cancer deaths are attributable to nutrition, lifestyles and occupational 
exposures to many carcinogens.  
Cancers arise in epithelial tissues (carcinomas), mesenchymal tissues (sarcomas), 
haemato-lymphoid system (leukemias and lymphomas) and other tissues of the body 
(Knowles et al. 2005). These cancers are both benign and malignant.  
Human exposures to a range of chemicals and toxins many of which may be 
potentially carcinogenic occur through air, water, diet, lifestyle and/or occupation. 
Biotransformation and metabolism of many of these chemicals are the primary cause of toxic 
manifestations. Cytochrome P450s (CYPs) form the major superfamily of enzymes involved 
in many of these Phase I metabolic reactions in addition to their roles in steroid genesis and 
drug metabolism. Given the widespread distribution and potentially multiple routes of 
exposure of many of these chemicals alternative strategies involving the use of 
chemopreventive measures to block or even reverse some of the genetic damage induced by 
these agents may be a viable approach.      
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2.2 Chemical carcinogenesis 
 
Chemical carcinogenesis typically involves a complex series of events starting with 
the bioactivation of the chemicals to DNA damaging metabolites followed by damage of 
cellular macromolecules and mutation fixation. Reports on increased incidences of nasal 
polyps among dippers and enhanced rates of scrotal cancer in English chimney sweeps were 
some of the early documented cases of chemical carcinogenesis (Poirier 2004).  
Early chemical carcinogenesis studies in the 1930s with attempts to isolate some of 
the carcinogenic constituents of coal tar has progressed rapidly ever since (Phillips 1983). An 
important landmark was the understanding that binding of reactive electrophiles (in case of 
genotoxic agents) to cellular macromolecules being associated with enhanced risk of 
carcinogenesis. However, these early studies believed the interaction to occur with proteins 
rather than DNA (Miller 1951). The work by Brookes and Lawley served to be some of the 
seminal work which demonstrated the binding of PAHs to DNA and its correlation to 
carcinogenicity (Brookes et al. 1964).  Subsequently, it has also become known that free 
radicals that may be generated by CYP mediated catalytic cycling of xenobiotics could also 
potentially cause free radical damage of cellular macromolecules. Non-genotoxic agents may 
cause damage by oxyradical formation, depurination, toxic cell death or even by modifying 
the effects of genotoxic agents (Yuspa et al. 1997). All these can be involved in the 
multistage process of chemical carcinogenesis that can be conceptually divided into 4 
component process: tumor initiation, tumor promotion, malignant conversion and tumor 
progression.  
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Tumor initiation  is a rare event the frequency of which is dependent on the carcinogen 
dosage. It may involve DNA adduct formation (as in case of genotoxic agents) leading to the 
inactivation of tumor suppressor genes and/or activation of protooncogenes or events such as 
methylation of the promoters of tumor suppressor genes (as in case of non-genotoxic agents) 
leading to their silencing. This requires the changes to occur in a population of dividing cells 
so as to ‘fix’ the mutations. In general a strong correlation has been observed between the 
extent of DNA adduct formation and tumor formation.  
 
Tumor promotion involves a clonal expansion of the initiated cells. Tumor promoters are 
agents that are generally non-mutagenic and non-carcinogenic by themselves but which 
enhance the carcinogenicity of tumor initiators. These usually possess multiple mechanisms 
of action and generally do not require any metabolic activation for the activity. They mainly 
serve to reduce the latency period for tumor formation when dosed in conjunction with the 
initiator. Tumor promoters generally bring about their effects through activation of cell 
surface receptors, stimulation of cell proliferation, perturbation of signal transduction 
pathways, inhibition of apoptosis or by modulation of cytosolic and nuclear factors. Agents 
capable of functioning both as a tumor initiator and promoter are regarded as complete 
carcinogens e.g.: 4-amino biphenyl. Tumor promotion is considered the chief rate limiting 
step in experimental carcinogenesis. 
 
Malignant conversion involves accumulation of further genetic changes leading to the 
transformation of preneoplastic cells to express a malignant phenotype. This often involves 
multi-focal changes in premalignant lesions such as up-regulation of AP-1, gene 
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amplification, exposure of cells to DNA damaging agents and over-expression of cell cycle 
regulatory proteases. The changes occurring may be reversible where regression of lesions 
occur when the promoting agent is removed prior to malignant conversion.  
 
Tumor progression involves acquisition of more aggressive characteristics by the malignant 
cells facilitating their spread and invasion beyond the primary site and often involves events 
such as complex genetic alterations (translocations, deletions, gene amplifications, 
duplications), ectopic changes in hormone production and activation of protooncogenes 
(through point mutations or gene amplifications) and inactivation of tumor suppressor genes. 
 
2.3 Chemical classes  
2.3.1 Polycyclic aromatic hydrocarbons (PAHs) 
 
PAHs are a class of more than 100 known compounds that are composed of variable 
numbers of fused benzene rings. They are ubiquitous environmental pollutants formed from 
the incomplete combustion of organic matter and are also generated as by-products from 
various industrial processes. Pure PAHs are usually colorless, white or pale yellow solids, 
generally odorless, but in some cases have a mild faint odor. These compounds almost most 
occur as complex chemical mixtures in nature. 
Considerable interest in PAHs stems from the ability of many of them to cause 
toxicity and cancers of various organs (Ramesh et al. 2004). PAHs are chemically inert, and 
they require metabolic activation to exert their biological effects (Weston et al. 2005). 
Benzopyrenes, are members of the PAH family of compounds. Two of these benzo(a)pyrene 
(BP) and benzo(e)pyrene (B[e]P) were used in various experiments in this study. 
 9
Benzopyrenes 
Benzopyrenes, prototypical carcinogens found generally with various other PAHs in 
tobacco smoke, charbroiled foods and in the combustion products of organic matter and 
various organic fuels are ubiquitous environmental pollutants (Hooven et al. 2005). BP, a 
highly carcinogenic PAH, has been a compound of extensive research interest since its first 
isolation by Kennaway et. al., in 1930s from 2 tons of coal tar pitch (Kennaway 1955). 
According to the International Agency for Research on Cancer (IARC) it has been placed 
under Group 2A (probably carcinogenic to humans) (IARC 1987). The structure of BP is 
shown in Figure 1(A). 
 
 
 
 
 
Figure 1: (A) Benzo[a]pyrene (BP)    (B) Benzo[e]pyrene (B[e]P) 
 
B[e]P  is  a structural isomer of BP. The low carcinogenicity of B[e]P in contrast to 
BP has caused very few studies to be carried out on B[e]P compared to BP. B[e]P is only 
weakly mutagenic and carcinogenic compared to BP and has been assigned  IARC rank of 
Group 3 (not classifiable as to the carcinogenicity to humans) (IARC 1987). The structure of 
B[e]P is presented in Figure 1(B).  
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However, because it is found with BP and other highly carcinogenic hydrocarbons in 
the environment, its effect on modulating the carcinogenicity of these hydrocarbons is to be 
addressed. 
 
2.3.2 Aromatic amines and heterocyclic amines 
Aromatic amines are carcinogens present in tobacco smoke, diesel exhaust and some 
cooked foods. They consist of one or more rings of unsaturated or cyclic hydrocarbons along 
with nitrate (NH2) groups. They  are implicated in cancers of the bladder, colon and ureter 
(Weston et al. 2005). 
 Heterocyclic amines are formed from high temperature cooking of foods (>1500C) 
mainly from pyrolysis of the amino acids, creatine and creatnine and sugars such as glucose. 
These substances have been found to be potent mutagens in Ames Salmonella assay and are 
carcinogens in laboratory animals (Layton et al. 1995). These have also been found to form 
liver tumors in primates (Adamson 1989). 
 
2.3.3 Aflatoxins 
These are chemicals which represent a family of structurally related 
difuranocoumarin derivatives produced by certain fungi (Aspergillus flavus and A. 
parasiticus) that contaminate peanuts, soybean and certain cereals. The production of theses 
toxins are affected by environmental and strain specific factors (Sudakin 2003). Aflatoxin B1 
and G1 are more mutagenic and carcinogenic than aflatoxin B2 and G2 (Weston et al. 2005). 
Exposure to aflatoxin B1 has been shown to be linked to enhanced risk of liver cancer in 
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human populations exposed to dietary aflatoxins in certain parts of China and Africa 
(Kensler et al. 2004).  
 
2.3.4 N-nitrosamines 
These are ubiquitous environmental pollutants found in certain foods such as cured 
meats, alcoholic beverages, certain cosmetics, oils and tobacco. N-nitrosamines can also be 
formed endogenously through nitrosation where an amine reacts with nitrate alone or in the 
presence of acid (Weston et al. 2005). Exposures to dietary nitrosamines have been 
associated with risk of esophageal and gastrointestinal cancers while exposure to  tobacco 
specific nitrosamines such as 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone have been 
associated with enhanced risk of lung cancer (Goldman et al. 2003).   
 
2.3.5 Non-genotoxic agents 
These are mainly agents which tend to bioaccumulate in biological systems (e.g.: 
pesticides, herbicides) and cause disease upon prolonged exposure. There is no conclusive 
evidence of their role in causing cancers but they may modify the effects of some of 
genotoxic carcinogens. In other cases they may manifest their effects by causing toxic cell 
death, oxyradical formation, disruption of hormonal balance, dysregulation of growth factors 
and by disruption of certain signaling pathways (Yuspa et al. 1997; Weston et al. 2005). 
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2.4 Metabolism of carcinogens 
Once internalized most chemical carcinogens are subject to competing processes of 
metabolic activation (Phase I reactions) versus detoxication (Phase II reactions). The 
metabolic route of some of the chemical classes listed above is discussed below. 
 
2.4.1 PAHs 
Benzopyrenes 
BP is one of the best characterized PAHs whose metabolism has been studied 
extensively. It acts as a ligand for Ahr, a basic helix-loop-helix (bHLH)/Per-ARNT-Sim 
(PAS) homology domain family of transcription factors. Various other planar aromatic 
compounds and many of their halogenated derivatives also act as Ahr ligands. BP has been 
found to be a strong Ahr ligand while B[e]P a weak Ahr ligand (Sterling et al. 1994). In 
vertebrates, Ahr exists in the cytosol complexed with a dimer of Hsp90 and several Hsp90 
accessory proteins (Puga et al. 2005). Ahr ligands following entry of the cell by diffusion, 
bind Hsp90 associated Ahr and subsequently cause a conformational change in Ahr leading 
to its increased affinity for DNA. The conformation change causes liganded Ahr to 
translocate to the nucleus, exchange Hsp90 for Arnt (aryl hydrocarbon nuclear translocator), 
another bHLH/PAS transcription factor ultimately leading to the formation of an Ahr, Arnt 
and ligand complex. This complex in turn binds to xenobiotic response elements (XRE) in 
the upstream regions of CYP genes leading to their enhanced transcription (Schmidt et al. 
1996; Vrzal et al. 2004). In some rare cases unliganded Ahr has been found to undergo 
nuclear translocation and it is suggested that a universal secondary mediator like cAMP may 
play a role in this mechanism (Oesch-Bartlomowicz et al. 2005). 
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Many studies on the mechanism of BP metabolism occurred during the period 
between 1950 -1990. The metabolism of BP generally proceeds in 2 phases; Phase I involves 
the conversion of BP to oxidized derivatives (epoxides, phenols, diols and quinines) and 
Phase II reactions involve the conversion of these derivatives to polar metabolites by 
conjugation with sulfate, glucuronic acid or glutathione (Osborne et al. 1987). 
The primary metabolites are three epoxides: 4,5-epoxide, 7,8-epoxide, and 9,10-
epoxide while 1,2-epoxide and 2,3-epoxide are theoretical intermediates that are non-
enzymatically converted to phenols. 4, 5-epoxide is the most stable of the epoxides that can 
be isolated. These products of initial oxidation are generated by the action of various CYPs 
principally CYP1A1, CYP1B1 and CYP3A4. The epoxides can subsequently be hydrolyzed 
to the corresponding  trans-diols/dihydrodiols (t-4,5 diol, t-7,8 diol or t-9,10 diol) by the 
action of epoxide hydratase (EH) or be converted non-enzymatically to phenols or undergo 
conjugation by glutathione S-transferases to form the corresponding glutathione conjugates 
(Gelboin 1980). Diols formed can exist in either the cis or trans configuration. All diols 
formed from PAHs other than BP in the presence of mammalian microsomal enzymes exist 
in the trans configuration. However, all diols formed enzymatically from BP are trans and (-) 
enantiomers of high optical purity (Gelboin 1980). 
1-OH, 3-OH, 6-OH, 7-OH and 9-OH are the 5 major phenol metabolites (with the 3-
OH, 7-OH and 9-OH metabolites being the most common) which can subsequently be 
converted to quinones/diones (1,3 quinone, 3,6 quinone and 6,12 quinone) or be conjugated 
to glucuronic acid by UDP glucuronsyl transferases (encoded by 2 gene families, UGT1 and 
UGT2 with several sub-families and members) to yield glucuronide conjugates. The 
glucuronide conjugates may be acted upon by β-glucuronidase present in the intestinal 
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microflora to release the parent compound, which, being electrophilic may attack DNA and 
other cellular macromolecules (Parkinson 2003). The quinones formed from the phenols may 
be conjugated to sulfates by sulfotransferases (encoded by 5 gene families, SULT1-SULT5 
with several subfamilies) and subsequently be converted to the corresponding sulfate 
metabolites or be conjugated to glutathione to produce glutathione conjugates (Guillen et al. 
2003). The phenols may also be directly converted to sulfate metabolites by the action of 
sulfotransferases. The formation of phenols, sulfates, glutathione and glucuronide conjugates 
are all considered to be more of detoxification pathways enhancing the hydrophilicity of the 
compounds and therefore aiding in their excretion from the system. Dihydrodiol metabolites 
can undergo further oxidation by CYPs (mainly CYP1B1 and CYP3A4) to produce 
dihydrodiol epoxides (Gelboin 1980) or may undergo conversion to more polar phenol diols 
(6-OH-7,8 diol, 1-OH-9,10 diol, 3-OH-9,10 diol, 9-OH-4,5 diol).  
The two common stereoisomeric dihydrodiol epoxides (of 4 possible forms) are r-7,t-
8 diol c-9,10 hydroxy BP/ (±)7α,8β-dihydroxy-9α,10α-epoxy-7,8,9,10 tetrahydroBP 
(BPDE1/syn isomer /cis isomer) and r-7,t-8 diol t-9,10 dihydroxy BP/ (±)7α,8β-dihydroxy-
9β,10β-epoxy-7,8,9,10 tetrahydroBP (BPDE2/anti isomer/trans isomer) (Kim et al. 1998; 
Rubin 2001). The preferred oxygenation site and subsequently the preferred dihydrodiol 
epoxide formed appears to depend on the CYP isoform catalyzing the process and hence is a 
function of the tissue or enzyme preparation used (Gelboin 1980). Both BPDE1 and BPDE2 
are reactive capable of binding to DNA, RNA and proteins forming bulky covalent addition 
compounds called adducts. The first experimental evidence that the anti isomer of BPDE 
may be the ultimate DNA binding metabolite was from work of Sims et. al. (Sims et al. 
1974). Both, BPDE1 and BPDE2 form a C-10 carbonium ion intermediate which is 
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responsible for their reactivity towards cellular nucleophiles such as DNA and proteins. 
Among the two stereoisomers BPDE2 has been found to be even more reactive than BPDE1 
and hence has been studied extensively (Kim et al. 1998). Both diol epoxides however are 
unstable in aqueous media and are hydrolyzed spontaneously to tetrols. BPDE1 can be 
hydrolyzed to 2 tetrols, (±)BP r-7,t-8 c-9,c-10 tetrahydrotetrol (RTCC), the major tetrol and 
(±)BP r-7,t-8 c-9,t-10 tetrahydrotetrol (RTCT), the minor tetrol while BPDE2 can also be 
hydrolyzed to 2 tetrols, (±)BP r-7,t-8 t-9,c-10 tetrahydrotetrol (RTTC), the major tetrol and 
(±)BP r-7,t-8 t-9,t-10 tetrahydrotetrol (RTTT), the minor tetrol. [The R, T, C system of 
nomenclature was suggested by the American Chemical Society where r = relative, the 
position to which all other positions relate, t = trans and c = cis]. Both BPDE1 and BPDE2 
can be reduced in the presence of NADH or NADPH to the corresponding triols. This 
reduction occurs non-enzymatically and is dependent on the tissue concentration of NADH 
or NADPH. The triols and tetrols are polar and undergo elimination through excretion. A 
summary of these various routes during the metabolism of BP is presented in Figure 2. A 
more detailed representation of the pathway leading to metabolic activation and the 
formation of adducts is presented in Figure 3. 
Metabolically activated BP (BPDE) binds DNA, RNA and proteins. The binding to 
proteins may be 10 times greater than to nucleic acids. Apart from BPDE, the oxides as well 
as diols are also known bind to proteins and nucleic acids (Osborne et al. 1987). Electron rich 
amino acids such as tyrosine, histidine and tryptophan may play a vital role in protein 
binding. When binding to DNA, deoxyguanosine appears to be the preferred base though 
adducts with all other bases of DNA are also known (Dipple et al. 1984). Some studies have 
also found modification of the phosphate backbone of nucleic acids. In case of binding to 
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RNA there seems to be some interaction of the diol epoxides with uracil residues (Gelboin 
1980). In case of guanine the major site of modification is the exocyclic amino group at 
position 2 though a minor product may also be formed at N-7. Adducts are also possible with 
the exocyclic amino group at position 6 of deoxyadenosine and the amino group of 
deoxycytidine (Dipple et al. 1984). The diol epoxide seems to be the predominant adduct 
involved in DNA binding.  
Given the lower carcinogenicity of B[e]P compared to BP relatively fewer studies 
have been carried out on this compound. Metabolism of B[e]P has been found to yield B[e]P-
4,5-dihydrodiol, 1-hydroxy-BeP and 3-hydroxy-BeP along with small amounts of B[e]P-
9,10-dihydrodiol and a few other secondary metabolites. Of these the 4,5 dihydrodiol appears 
to be the major metabolite. Other studies have also found an unidentified phenol (probably 1-
hydroxy-BeP), 3-hydroxy-BeP and a quinone as metabolites but their proportions are much 
lower than B[e]P-4, 5-dihydrodiol. However, B[e]P-9,10-dihydrodiol is the only derivative 
whose metabolism has been studied. On incubation of this derivative with liver microsomal 
about 13% was converted to 9,10-epoxy-11,12-dihydroxy-9,10,11,12-teterahydro-BeP while 
the rest was recovered as B[e]P-4,5,9,10-tetrahydrotetrol and 2 triols. 9,10-epoxy-11,12-
dihydroxy-9,10,11,12-teterahydro-B[e]P reacts directly with DNA, the principal adducts 
having C9 of guanine attached to exocyclic N2 of guanine. A few other minor adducts 
including ones with deoxyadenosine have also been found (Osborne et al. 1987). 
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Figure2: Metabolic pathways of BP. The different routes of metabolism listed here are 
however not exhaustive. 
 
 
 
 
Figure 3: The metabolic activation of BP has been widely studied. (1) CYP1A1 and 
CYP1B1 catalyze the conversion of the parent compound to arene oxides. (2) Arene oxides 
are converted to dihydrodiols by EH (3) The resulting dihydrodiols are further oxidized at the 
site of the olefinic bond (4) Vicinal diol epoxides are highly unstable and undergo 
spontaneous arene ring opening to yield carbocation. (5) The electrophilic carbocation can 
form a covalent bond with exocyclic amino group of deoxyguanosine. The resulting adducts 
resides in the minor groove of DNA. 
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2.4.2 Aromatic amines and heterocyclic amines 
 The metabolism of aromatic amines is rather complex. They may be converted to an 
aromatic amide catalyzed by acetyl co-enzyme A dependent acetylation or may undergo N-
oxidation to give N-hydroxylated products which may subsequently be protonated by acidic 
conditions in the urinary bladder giving rise electrophiles capable of binding DNA. The 
initial activation step of both aromatic amines and amides is through CYP1A2 mediated N-
oxidation (Weston et al. 2005). 
Heterocyclic amines are bioactivated by CYP1A2 mediated N-hydroxylation 
followed by enzymatic O-esterification. The nitrenium ion is likely to be the ultimate 
carcinogen capable of adduct formation (Goldman et al. 2003). 
 
2.4.3 Aflatoxins 
Aflatoxins may be activated by various CYPs (CYP2A3, CYP1A2, CYP2A6, 
CYP3A4, and CYP3A5). In case of aflatoxin B1, the process involves a CYP3A4 or 
CYP1A2 mediated oxidation at the exo 8, 9 position to form an electrophilic exo 8, 9 epoxide 
which can subsequently bind to DNA and proteins and form adducts. Formation of these 
adducts has been shown to cause G:C to T:A transversion at codon 249 of the p53 tumor 
suppressor gene (Kensler et al. 2004). Formation of CYP1A2 mediated aflatoxin M1 is 
considered a detoxification pathway (Sudakin 2003). 
 
2.4.4 N-Nitrosamines 
Endogenous nitrosamines form during the reaction of an amine with a nitrate alone or 
a nitrite in the presence of an acid. Dietary and tobacco specific nitrosamines constitute some 
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of the exogenous sources of nitrosamines. N-nitrosodimethylamine formed from exposure to 
nitrosamines undergo enzymatic α-hydroxylation (CYP2E1/ CYP2A6 mediated) to form an 
unstable α-hydroxynitrosamine which subsequently hydrolyzes to an aldehyde and a 
monoalkylnitrosamine. The monoalkylnitrosamine can subsequently release a carbocation 
which can alkylate DNA bases.  
 
2.5 DNA damage  
Exposures to carcinogens through various routes lead to DNA damage. The damage 
may involve formation of addition compounds by covalent attachment to DNA bases (adduct 
formation), alterations in DNA structure (single and double strand breaks, DNA strand cross-
links, chromatid exchanges), oxyradical damage of bases, transitions, transverisons, 
dimerization, deamination as well as epigenetic changes (Yuspa et al. 1997; Weston et al. 
2005). 
Most carcinogens are mutagens causing heritable changes in the structure of DNA.  
Different nucleophilic sites on DNA form targets for attack by different adduct forming 
species. These include N1, N3 and N7 of adenine, N3 of cytosine, O2, N3 and O4 of 
thiamine and N2, O6 and N7 of guanine. DNA adduct formation may involve the addition of 
just a portion of the chemical carcinogen such as a small alkyl group (as in the case of 
carcinogens like N-nitrosamines, N-alkylureas, mustards and haloalkanes) or the entire 
carcinogen  leading to the formation of large, bulky DNA adducts (as in case of many PAHs) 
(Weston et al. 2005). In many cases these changes lead to the formation of ‘signature’ 
mutations in certain key oncogenes and /or tumor suppressor genes. For example, in many 
cases of tobacco smoke induced lung cancer the common targets for adduct formation appear 
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to be the ras oncogene as well as the p53 tumor suppressor gene.  Most cases of aflatoxin 
induced hepatocarcinomas (from either China or South Africa) were found to harbor G → T 
transverisons in the 3rd position of codon 249 of p53 (Yuspa et al. 1997; Weston et al. 2005). 
Activated benzopyrenes bind preferentially to the exocyclic amino group of 
deoxyguanosine (N2) to form (7R)-N2-(10[7b, 8a, 9a-trihydroxy-7,8,9,10-tetrahydro-
benzo[a]pyrene]yl)-deoxyguanosine (BPdG) adducts which appears to be the most common 
adduct of BP though adducts with other bases in DNA have also been reported. With regard 
to aromatic amines the C8 of deoxyguanosine appears to be the predominant site for adduct 
formation though adducts with C8, N2 and O6 are also possible (Weston et al. 2005). 
Heterocyclic aromatic amines also have a preference for the C8 and amino groups of purines, 
especially deoxyguanosine for forming adducts (Dipple 1995). Aflatoxin B1 and G1undergo 
oxidation at the 8, 9-position to form N7 deoxyguanosine adducts. This in turn could undergo 
ring opening to form two pyrimidine adducts  N-nitrosamines upon metabolic activation 
bring about alkylation of DNA at some of the similar sites on DNA bases as mentioned 
above though the N7 of guanine appears to be the preferred site.  
 Apart from these, oxidative damage of DNA from various endogenous and/or 
exogenously sources of oxygen radicals can lead to the formation of thymine glycol or 8-
hydroxydeoxyguanine adducts. The catalytic cycling of BP, endogenous lipid peroxidation 
and catalytic cyclic of some enzymes include some of these (Guengerich 2001). Etheno 
adducts can result from reaction of the bases in DNA with xenobiotics such as urethane and 
chemicals such as carbon tetrachloride and ethanol. 
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2.5.1 DNA repair 
  Maintenance of the genome integrity may be achieved at various levels such as by 
prevention of carcinogen activation, prevention of interaction of the activated carcinogen 
with the target site, abrogation of the damage caused, or various combinations of these. 
Impaired capacity for DNA repair is associated with various cancers and syndromes.  More 
than 140 gene products are implicated to play roles either directly or indirectly in different 
mechanisms of DNA repair mechanisms (Knowles et al. 2005). There are six main 
mechanisms of DNA repair: direct DNA repair, nucleotide excision repair (NER), base 
excision repair (BER), mismatch repair, non-homologous end joining and homologous 
recombination (Yuspa et al. 1997; Weston et al. 2005). 
  Generically DNA repair involves damage recognition, excision of the damaged 
strand, resynthesis and ligation. All these repair mechanisms involve multiprotein complexes 
with many of their components being involved in common in more than one repair process 
(Weston et al. 2002). 
Direct DNA repair involves alkytransferases which remove alkyl moieties from 
alkylated bases followed by transfer of the moiety to a cysteine in the active site of the repair 
enzyme. The best known example of this mechanism is the removal of O6-methyl guanine.  
NER and BER are similar with both involving multi-protein complexes which 
recognize the damage, remove the damage, fill in the gaps created and finally seal the nick. 
NER however, is employed in the repair of large bulky adducts such as those of 
benzopyrenes while BER is typically involved in the removal of smaller alkyl groups.  
DNA mismatches involving single base mismatches due to errors in DNA repair or 
replication can be corrected by mismatch DNA repair mechanism which involves removal of 
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large pieces of mismatched DNA using protein complexes that bind to the mismatch and the 
nearest unmethylated adenine in the sequence GATC, followed by resynthesis of excised part 
by DNA polymerase and finally ligation by a ligase complexed to the polymerase.  
 Large bulky adducts such as those of BP can also distort DNA causing it to break.  In 
addition, other mechanisms such as exposures to ionizing radiations and a damage tolerance 
mechanism known as post explicative repair also causes DNA double strand breaks. These 
double strand breaks may be repaired by homologous or non-homologous recombination 
mechanisms. Homologous recombination involves the simultaneous resection of both strands 
followed by invasion of the homologous duplex by 5’ tails of the disrupted DNA, resynthesis 
followed by polymerization and ligation. 
 Non-homologous end joining is a repair mechanism that is homology independent. 
The breaks may be symmetric or asymmetric; in case it is asymmetric resection occurs to 
create blunt ends before they are joined. This method of repair is therefore prone to 
introduction of small deletions in the sequence of the repaired DNA. 
 
2.6 Potential impact on hormonal carcinogenesis 
BP is an inducer of steroid hydroxylases, CYP1A1 and CYP1B1, which in turn bring 
about the metabolism of BP to reactive intermediates. These enzymes along with CYP3A4 
also play a vital role in the oxidative metabolism of two of major natural estrogens, estrone 
(E1) and estradiol (E2) (produced by the ovaries) as well as other synthetic estrogens such as 
17α ethyinylestradiol (Liehr et al. 1990). The major pathway of estrogen oxidation involves 
their P450 mediated hydroxylation to form catechol estrogens (CEs), their 2-OH and 4-OH 
derivatives, and 16α-OH metabolite (Cavalieri et al. 1997). Although these CEs can be 
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inactivated through conjugation, their incomplete or ineffective conjugation may lead to the 
production of reactive semiquinones and/or quinones radicals. These quinones can 
subsequently be inactivated by conjugative mechanisms. However, incomplete removal may 
allow them to bind to DNA and form stable DNA or depurinating DNA adducts. The 
formation of N7 guanine adducts by CE-3,4-quinone is thought to be a tumor-initiating event 
(Cavalieri et al. 1997). Apart from this, free radicals generated from the quinone-
semiquinone redox cycling of estrogens can lead to free radical damage (Kirkman 1959; 
Liehr et al. 1990). Further, the 4-OH and 16α-OH metabolites of estrogen are found to have a 
potent cell proliferative effect in estrogen responsive tissues  
 
2.7 Chemoprevention 
Given the ubiquitous nature of benzopyrenes a complete avoidance of their contact is 
impossible. An alternative more practical approach may therefore involve reducing their 
uptake, preventing their metabolism or preventing the activated metabolites from 
reaching/interacting with the target site. The use of agents (natural, synthetic, biological or 
chemical) which may reverse, suppress or prevent the carcinogenic process at various phases 
of the multistep carcinogenic process may form a viable strategy. This constitutes the concept 
of chemoprevention. Though known for about four decades or so a greater insight into the 
idea was brought by two pioneers in the field, Lee W.Wattenberg and Michael B. Sporn. 
Initially called ‘chemoprophylaxis of carcinogenesis’ by Wattenberg (Wattenberg 1966), the 
term ‘chemoprevention’ was coined only later by Sporn  et al., (1976). The original concept 
of chemoprevention was to inhibit or delay the occurrence of cancers by agents that would 
block one or more pathways in the induction of cancer. However, the concept has expanded 
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over the years to include agents which would even reverse the carcinogenic process by 
transforming malignancy to pre-malignancy. 
 
2.7.1 Chemopreventive agents  
  Currently there are approximately 400 compounds being studied as potential 
chemopreventive agents of which around 10% are in clinical trials 
(http://www.cancer.gov/cancertopics/factsheet/Prevention/chemoprevention). 
Chemopreventive agents can be classified into 4 main categories: blocking agents, agents 
reducing tissue vulnerability to carcinogenesis and suppressing agents (Wattenberg 1997). 
 Blocking agents act through prevention of carcinogen activation, enhancement of 
carcinogenic detoxification or prevention of activated metabolites from reaching critical 
target sites. Agents reducing tissue vulnerability to carcinogenesis act through effecting 
cellular maturation, reducing the activity of the target cells, decreasing cell proliferation or 
modulating signal transduction and hormone/growth factor activity. 
Suppressing agents prevent the evolution of the neoplastic process in cells that may be on the 
verge of becoming malignant. Some suppressing agents may act by producing differentiation 
and inhibiting cellular proliferation. Another large group of compounds not fitting into any of 
these categories have the capacity to inhibit components of the arachidonic acid pathway and 
induce antioxidant enzymes. 
 Ideal chemopreventive agents are ones which combine multiple mechanisms of 
action, have low toxicity, high efficacy, are easily acceptable in intervention strategies and 
are economically viable (Egner et al. 2001). 
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Chlorophyllin (CHL) 
Porphyrins are compounds with four pyrrole nuclei (a five-membered heterocyclic 
aromatic ring compound with the formula C4H5N) joined by -CH- bridges.  
Porphyrins, both natural as well as modified versions are generally, effective antimutagens and 
anticarcinogens against heterocyclic amines and various other mutagens possessing polycyclic 
structures. Hemin (the natural porphyrin found in hemoglobin and myoglobin), copper 
pthalocyacnin (a blue pigment similar in structure to hemin) and chlorophyll (the green pigment in 
photosynthesizing plants) have all been found to be effective antimutagens (Hayatsu 1995). The 
structures of these compounds are presented in Figure 4. 
Chlorophylls and even more so CHL have been gaining prominence over the last decade as 
effective chemopreventive agents (Dashwood 1997b). Commercially available CHL consists 
mainly of a trisodium copper salt apart from small amounts of mono- and di-carboxylic acid 
chlorins (Dashwood 1997b). 
Though several medical and clinical uses of CHL exist (Kephart 1955) its increasing use in 
cancer biology stems from its ability to exhibit various activities in in vitro and in vivo studies 
making it an attractive chemopreventive agent.  Its has been found to be antimutagenic being 
effective against various chemicals such as aflatoxin B1, BP, heterocyclic amines, coal dust and 
airborne particles (Terwel et al. 1985; Ong et al. 1986; Dashwood et al. 1991; Warner et al. 1991). 
Anticlastogenic activities of CHL have been demonstrated in a few studies (Sarkar et al. 1996; 
Negraes et al. 2004). CHL has also been shown to exhibit antigenotoxic (Bez et al. 2001; Torres-
Bezauri et al. 2002), anticarcinogenic (Park et al. 1996; Reddy et al. 1999), antioxidant (Kamat et 
al. 2000; Kumar et al. 2004)) apoptosis inducing (Diaz et al. 2003; Chiu et al. 2005) and immuno 
modulatory properties (Yun et al. 2005; Sharma et al. 2006).   
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Figure 4: Structures of some of the biologically important metalloporphyrins. The groups 
that differ in CHL compared to chlorophyll are circled. The positions occupied by sodium 
(Na) can also be occupied by potassium (K) depending on reaction conditions during the 
conversion of chlorophyll to CHL. Commercial CHL is mainly the trisodium salt shown here 
along with small amounts of mono-sodium and di-sodium salts. 
 27
 
The most conclusive evidence of CHL as an anticarcinogenic agent probably comes 
from its role in the chemoprevention of hepatocarcinoma (liver cancer) in aflatoxin endemic  
areas of the world such as China (Kensler et al. 2004). Chronic hepatitis B virus (HBV) 
infection along with exposure to aflatoxins through diet contributes to extremely high risk of 
liver cancer in Quidong. Exposure to aflatoxins is also widespread in Beijing, Taiwan, certain 
parts of Africa and other developing areas of the world leading to high risk of liver cancer of 
exposed populations. While primary intervention through HBV vaccination has helped to 
some extent, secondary intervention strategies through the use of CHL or other drugs such as 
oltipraz have greatly helped reduce the risk of disease through various mechanisms discussed 
below. Administration of CHL helped reduce AFB1- N7-guanine adducts by as much as 
55%. In this aspect CHL has an advantage over other agents such as oltipraz, given its low 
cost and high efficacy leading to its easy adoptability by a larger section of at risk human 
populations in developing areas (Sudakin 2003; Kensler et al. 2004). 
However, there are conflicting reports with regard to the use of chlorophyll or CHL 
as chemopreventive agents of choice with some studies pointing to chlorophyll being a better 
choice (de Vogel et al. 2005) others CHL (Terwel et al. 1985) and yet others showing both to 
be equally effective (Bez et al. 2001). The nature of the carcinogen, system under study and 
end points observed may contribute to some of the differences. Again, with respect to CHL, 
there are some studies which point not only to the lack of a positive modulatory effect 
(Torres-Bezauri et al. 2002) but also to an enhancement of the tumor promotion (Nelson 
1992) or increase in mutation frequency (Negraes et al. 2004). In another study, CHL when 
administered after or during and after carcinogen exposure (1, 2 dimethyl hydrazine) 
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enhanced the number of colon tumors produced in rats. Additionally, in the same study, 
when a range of CHL concentrations were administered through drinking water, following  
exposure to 1,2 dimethyl hydrazine (DMH) or 2-amino-3-methylimidazo[4,5-f]quinoline 
(IQ), the lowest concentration of CHL (0.001%) enhanced the multiplicity of DMH induced 
tumors while having no promotion effect on tumors induced by IQ (Dashwood et al. 2001). 
Thus, here too the test species involved, carcinogen used, the concentration of CHL 
employed, the route of administration and temporal aspects of the exposure protocol may all 
be key factors playing an important role in deciding the final role of CHL as an inhibitor or a 
potentiator. 
Mechanisms of action 
Several mechanisms of CHL action have been proposed. By acting as a suicidal 
inhibitor, CHL has been shown to bring about non-specific inhibition of CYPs probably 
involving destruction of the heme prosthetic group of CYPs (Yun et al. 2005). However, 
other investigations involving spectral studies have proposed that the inhibition may be rather 
indirect by interacting with NADPH-cytochrome P450 reductase, a rate limiting enzyme in 
mixed-function oxygenase system rather than involving any direct interaction with P450. 
This interaction may involve a physical interaction of CHL with NADPH-cytochrome P450 
reductase preventing docking P450 with or its role as an alternative electron acceptor 
interfering with the electron flow from NADPH to P450s (Tachino et al. 1994).  
In addition to inhibition of Phase I enzymes, CHL has also been reported to enhance the 
expression of Phase II detoxification enzymes. One study revealed that following oral 
administration, CHL enhanced the amounts of hepatic glutathione S-transferase in lactating 
mice (Singh et al. 1996). Studies on induction of NADPH quinone reductase (NQO1), a 
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quintessential Phase II enzymes showed CHL and chlorophylls to be significant inducers of 
NQO1 (Fahey et al. 2005). 
The most widely accepted mechanism is the role of CHL as an ‘interceptor molecule’ 
or ‘desmutagen’ wherein CHL in addition to acting as a free radical scavenger also forms 
tight molecular complexes with the activated carcinogen preventing it from interacting with 
DNA or other cellular macromolecules (molecular trapping). Studies indicate that the 
mutagen should possess at least 3 fused rings with some degree of planarity in order to 
complex with CHL (Arimoto et al. 1993). Two forces play a key role in complex formation; 
van der Walls forces between overlapping ring systems of the mutagen and CHL and ionic or 
H bonds between substituents on the mutagen and carboxyl groups of the inhibitor 
(Dashwood et al. 1996).  In case of BP, hypothetical complexes between CHL and BPDE 
(benzo[a]pyrene –trans-7, 8-dihydrodiol-9, 10-epoxide) are thought to be stabilized by 
multiple π-π interactions between CHL and BPDE. Following sequestration of the activated 
carcinogen (BPDE) by CHL they may be degraded to more hydrophilic tetrols and excreted 
(Tachino et al. 1994).  
A relatively recent study has also shown the role of CHL as a modulator of 
carcinogen uptake and transport. The study examining the effects of a range of CHL 
concentrations on the transport of 3 different carcinogens, dibenzo(a,l)pyrene (DBP), 2-
amino-1-methyl-6-phenylimidaza-[4,5-b]pyridine (PhIP)  and AFB1 across Caco-2 cell 
monolayers from the apical to the basolateral side found that all concentrations of CHL 
reduced the transport of DBP from the apical to the basolateral side though not much effect 
was observed on the transport of the other two carcinogens (Mata et al. 2004). Though there 
have hardly been any further studies on this aspect of CHL, it may be possible that CHL may 
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have a modulatory effect on the intake and transport of BP. CHL has been reported to be a 
membrane stabilizer and hence it may be reasonable to make the above assumption (Dhir 
1989 ). 
As further mechanistic studies and intervention trials are conducted with CHL a 
greater number of mechanisms of action and properties of CHL may be unveiled. 
 
2.8 Cytochromes P450 (CYPs) 
 Most carcinogens (including benzopyrenes) requiring metabolic activation to render 
them carcinogenic and are often bioactivated by various members of the cytochrome P450s. 
They enzymes possess some of the broadest range of substrate specificities with some being 
highly specific (such as those involved in steroid anabolism, mitochondrial and bacterial 
P450s) and yet others (such as those involved in oxidation of various substrates) exhibiting a 
broad range of catalytic activities (Guengerich 1991; Ioannides 1996; Lewis 2001). These 
proteins have been reported to be present in most tissues though mainly concentrated in the 
liver (1-2% of an individual hepatocyte by weight) and localized to the endoplasmic 
reticulum (12-15%) and to some extent the mitochondria. Some P450s have also been 
reported to be translocated outside the plasma membrane where they may have role in 
development of immune responses.  As of 2005 there were reportedly >4500 named P450 
genes (http://drnelson.utmem.edu/CytochromeP450.html). 
Structurally, all P450s seem to contain an 8-10-residue signature motif (F G/S x H/R 
x C x G/A) with a highly conserved cysteine residue serving as a ligand for a central heme 
(Lewis 2001). The central heme is bound to the four pyrrole nitrogens leaving room for two 
additional ligands in the axial positions. One of these ligands above the porphyrin plane is 
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satisfied by the invariant cysteine and the other ligand below the plane generally being a 
hydroxyl group related to a tyrosinyl radical or an exchangeable water molecule (Janig et al. 
1984; Porter et al. 1991). 
P450s are mainly mixed function oxygenases which require a source of electrons to 
function. The electrons which are generally derived from NADPH are delivered to the iron in 
the CYP by a flavoprotein, NADPH cytochrome P450 reductase in case of P450s bound to 
the endoplasmic reticulum or by another protein, ferrodoxin reductase (adrenodoxin 
reductase in case of the adrenals) via an iron-sulfur cluster called ferrodoxin to mitochondrial 
P450s (http://drnelson.utmem.edu/CytochromeP450.html). In some less common cases, the 
routing of electrons from NADPH is may be carried out through cytochrome b5 and NADPH 
cytochrome b5 reductase or microsomal heme oxygenase (Shen et al. 1989). 
The CYP superfamily is divided into families, subfamilies and individual genes based 
on primary amino acid sequence similarities. P450 protein sequences with ≤ 40% amino acid 
sequence identity are grouped into different families. Members within a family are divided 
into sub-families and individual genes (http://drnelson.utmem.edu/CytochromeP450.html). 
P450s catalyze the metabolism of various endogenous and exogenous substrates.  In 
general, P450s in most non-animal species seem to be involved chiefly in the metabolism of 
endogenous substrates.  Different P450 isoforms have been found to be involved in the 
biosynthesis and metabolism of steroids, fatty acids, prostaglandins, prostacyclins, 
thromboxanes, Vitamin D, bile acids and also in the metabolism of a large number of drugs 
(http://medicine.iupui.edu/flockhart/). 
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2.8.1 Regulation of CYPs 
The amount of functional P450s is subject to considerable inter-individual variation. 
Several factors such as the presence of polymorphisms in P450 genes, use of different 
nuclear receptors, post-transcriptional (mRNA stabilization) and post-translational (enzyme 
stabilization) mechanisms appear to play a role to regulate the abundance and activity of 
P450s (Figure 5). Most CYPs however appear to be regulated at the transcriptional level and 
many seem to be subject to tissue specific regulation.  
 
 
 
 
 
 
 
Figure 5:  Multiple levels in the regulation of P450s. The different levels at which CYPs are 
regulated are indicated in red. The specific CYP isoform(s) regulated by the respective 
mechanism(s) is indicated below each mechanism. 
 
The most well characterized P450 regulatory mechanisms are with respect to 
members of the CYP1 family, regulated by the Ahr-Arnt mechanism (discussed in detail in 
the section on BP in 2.4.1).  
Transcriptional regulation of the CYP2 family involves various receptors related to 
the nuclear receptor family such as the constitutive androstane receptor (CAR) in the case of 
CYP2B and the retinoic acid receptor (RAR) in the case of CYP2C (Lewis 2001). In 
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addition, members of the CYP2B family are also regulated by protein kinase A (PKA). 
mediated phosphorylation (Oesch-Bartlomowicz et al. 2003). The regulation of CYP2A and 
CYP2D however, are, mediated by HNF-4 (hepatic nuclear factor-4). The regulation of 
alcohol inducible CYP2E1 appears to take place at multiple levels including post- 
transcriptional and post-translational. Diabetes and fasting appear to have a stabilizing effect 
on CYP2E1 mRNA. Presence of chemical inducers also stabilize the protein by preventing 
its phosphorylation by PKA and subsequent degradation (Oesch-Bartlomowicz et al. 2003). 
CYP3 family members are mainly regulated by members of the orphan nuclear 
receptor family, glucocoticoid receptor (GR) and pregnane-X-receptor (PXR). 
The CYP 4 family is regulated via another nuclear receptor, peroxisome proliferator 
activated receptor (PPAR).  
Various other receptors involved in the modulation of different P450s associated with 
the metabolism of different endogenous substrates are present in Table 1. 
Other mechanisms of regulation include regulation by cyclic AMP (cAMP) in the 
case of trophic hormones (Porter et al. 1991), use of cis and trans acting elements along with 
co-activator and repressor proteins, cross-talk between specific nuclear receptors (Lewis 
2001) and in some rare cases by neonatal imprinting (Porter et al. 1991). In addition, certain 
chemicals can inhibit P450s through several mechanisms such as heme ligation, heme adduct 
formation, competitive inhibition, formation of reactive intermediates or various 
combinations of these and can therefore modulate CYP expression (Lewis 2001).  
Polymorphisms in P450s have mostly been addressed in the context of ‘drug 
metabolizer’ phenotypes and susceptibility to diseases. However, the underlying cause of 
these is the differential expression of the respective P450s caused by the respective 
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polymorphisms. For example, *2A and *2B variant alleles of CYP1A1 gene have a T3801C 
base change introducing a new MspI restriction site in intron 6. These variant alleles are 
associated with enhanced enzyme inducibility and subsequently an elevated risk of smoking 
associated lung cancer in Japanese and Caucasian cancer patients (Chowbay et al. 2005). The 
P450s form one of the most polymorphic groups of enzymes. A comprehensive list of 
different polymorphisms in P450 enzymes can be found at 
(http://www.imm.ki.se/CYPalleles/).  
In summary, the overall amounts of P450s are governed by the concentration of 
inducers and repressors, polymorphisms, and cross-talk with various other receptors, ligands, 
proteins, and signaling molecules with other factors within the cell. 
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Table 1: List of receptors and factors associated with the induction of some of the P450s 
involved with endogenous substrate metabolism 
CYP Receptor/Factor 
Trophic hormone as 
mediating factor 
7 FXR, LXR - 
11 SF-1 
ACTH (adrenals), LH 
(testis) 
17 SF-1 
ACTH (adrenals), LH 
(ovary) 
19 SF-1, ER FSH (ovary) 
21 SF-1 ACTH (adrenals), 
26 RAR, RXR - 
27 VDR PTH (kidney) 
 
FXR = farnesoid X receptor (down-regulator of bile acid synthesis), LXR = liver X receptor (up-regulator of bile acid synthesis), SF = 
steroidogenic factor 1, ER = estrogen receptor, VDR = vitamin D receptor, ACTH = adrenocorticotrophic hormone, LH = lutenizing 
hormone, FSH = follicle stimulating hormone, PTH = parathyroid hormone 
 
2.9 Biomarker Concept 
Traditional epidemiology has investigated the relationship between exposure and 
disease. The extent that identification of preclinical changes was possible assisted the better 
understanding of that relationship. Before the introduction of biomarkers the intermediary 
steps in the exposure-disease progression were considered to be unknown (a “Black Box”). 
The introduction of biomarkers has assisted greatly in the effort to see into the “Black Box.” 
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(Hirschhorn et al. 2002; Wogan et al. 2004). The biomarker concept in molecular 
epidemiology has been refined significantly since it was articulated by Perera and Weinstein 
in 1982 (Perera et al. 1982; Perera et al. 2000) and promises to elucidate a large number of 
intermediary steps that have the potential to impact upon risk of disease as depicted in the 
schematic representation below. 
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Schematic representation of the components of the exposure-disease continuum emphasizing 
the need for development of biomarkers of human cancer risk at every pathologic stage 
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A biomarker is a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes or pharmacological responses to 
therapeutic intervention (Srivastava et al. 2002). In order for biomarkers to be valuable they 
need to be sensitive, specific and predictable in the manner they change between the normal 
and the diseased states. 
Human chemical carcinogenesis generally has a long latency.  For decades, a 
pathology approach has used microscopy of biopsied slides to understand structural changes 
underlying the transformation process. Unfortunately, when these discernable or measurable 
changes have occurred many molecular changes have also occurred and it is usually too late 
for successful intervention (Negm et al. 2002). 
Emphasis needs to be on the development of early biological markers of the disease 
process prior to the transformation of normal cells. Detecting and understanding these 
changes quickly and accurately will he greatly aid in the early detection of cancers. In 
addition it will also help shape preventive and therapeutic measures and also predict 
prognostic outcomes. 
Conventional epidemiology, which draws on casual associations between certain 
exposures/lifestyles and risk of certain cancers, requires studies of population risks and may 
at best help identify and monitor other individuals or populations at risk; however, it cannot 
help early detection of cancer. Recent technological advances have helped in a greater 
understanding of the cancer process at the molecular level and in turn has helped develop 
biomarkers for early detection and risk assessment of different exposure scenarios 
(Srivastava et al. 2002). 
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Molecular epidemiology (the use of molecular and biochemical tools to detect early 
molecular changes associated with cancer risk) can now be used in conjunction with 
conventional epidemiological studies to detect some cancers in their early stages (Weston et 
al. 2005). Thus, they are intended to supercede clinical endpoints. 
 
2.9.1 Types of cancer biomarkers 
According to schematic representation above there is a hierarchy of biomarkers: 
general exposure biomarkers include metabolites in urine, saliva and other body fluids (e.g., 
cotinine and cortisol signaling exposure to nicotine and stress, respectively); biomarkers of 
biologically effective dose include carcinogen-protein or carcinogen-DNA adducts derived 
from blood (these are surrogates for potential genetic damage in the DNA of target tissues). 
BP-DNA adducts have been valuable in the integration of dose and biological propensity of 
DNA damage from PAHs (Perera et al. 1982). Exfoliated aflatoxin-guanine adducts in urine 
(AFB1-N7-dG) have been identified as a risk factor for hepatocellular cancer in populations 
potentially exposed to AFB1 in china and S. Africa (Kensler et al. 2004). 
In conjunction with these studies, there is the possibility to assess cancer 
susceptibility based on genetic variation. When the continuum of events from exposure to 
disease is considered, it should be noted that the contribution from the Human Genome 
Project (HGP) has been highly significant in the arena of genetic polymorphisms. Recent 
studies have shown that molecular epidemiologic association studies offer a powerful 
approach to the identification of genetic variants that influence disease susceptibility 
(Hirschhorn et al. 2002; Consortium 2003). Some of these pertain to potential markers of 
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susceptibility in the context of a specific exposure scenario, for example: bladder cancer and 
the NAT2 genotype in dye workers and in tobacco smokers (Green et al. 2000). 
Gene expression patterns have been used to compare different types of tumor, 
different tumor grades and tumor response to treatment (Lonning et al. 2005). However, from 
the perspective of carcinogenesis, recent studies have identified gene expression patterns 
within the continuum of the carcinogenic process. One such study described gene expression 
patterns in peripheral white blood cells in response to exposure in tobacco smokers (Lampe 
et al. 2004). 
In addition to gene expression studies, gene mutation studies have been important 
biomarkers that have been used for both understanding etiology (Olivier et al. 2004) and 
predicting outcome (Jackson et al. 2003). A prime example is that of p53 mutations. There is 
good evidence that exposure to specific agents results in specific or limited types of p53 
mutations in certain types of cancer; for example AFB1 and liver cancer, polycyclic aromatic 
hydrocarbons and lung cancer, and UV irradiation and skin cancer (Olivier et al. 2004). From 
prospective studies of AFB1 related liver cancer, p53 mutations have been identified in 
fragments of tumor DNA exfoliated into blood serum before clinical manifestation of 
disease. There by providing a biomarker for early liver cancer detection in high AFB1 
exposure regions of the world.  
Many genes including oncogenes and tumor suppressor genes are regulated by 
epigenetic mechanisms. Dysregulation of epigenetic control of various genes such as p15, 
p16, APC and VHL have been observed to occur early on in several cancers (Negm et al. 
2002).    
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Other penitential biomarkers include measurement of chromosomal aberrations, point 
mutations and loss of heterozygosity in DNA from various body fluids of cancerous patients. 
Presence of anti-apoptotic proteins in the urine of patients with recurrent bladder cancer has 
been reported and has been found to be a useful biomarker (Smith et al. 2001). 
 
2.9.2 Challenges in using biomarkers 
In order for biomarkers to be used efficiently and reliably they will need to be highly 
sensitive and specific. Though there has been significant progress in the field of cancer 
biomarker research over the last two decades it has still not reached a level of confidence for 
application in the clinical setting, and validation studies are required. Some of the biomarkers 
currently in use such as prostrate specific antigen (PSA) for prostrate cancer, CA125 for 
ovarian cancer are not very specific for their respective cancers. In addition, in this time of 
rapidly advancing technological developments, there is a need for more effective as well as 
novel cancer biomarkers. 
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2.10 Statement of the problem 
Benzopyrenes, a class ubiquitous environmental contaminants are procarcinogens. 
Due to their widespread distribution, alternative strategies such as the use of 
chemopreventive measures to mitigate some of the genetic damage caused by these 
chemicals may form a practical approach. This study was designed to seek biomarkers of BP 
exposure (using microarrays) which could subsequently form targets for chemopreventive 
intervention. CHL, a water soluble metalloporphyrin was used as a chemopreventive agent in 
all these studies. Also, since benzopyrenes are procarcinogens requiring metabolic activation 
by CYP1 enzymes for their conversion to DNA damaging metabolites, the effect of CHL on 
mitigating the expression of CYP1 enzymes, in addition to their efficacy in preventing the 
interaction of the activated BP metabolites with cellular macromolecules such as DNA as 
measured by RT-PCR and BP-DNA adduct analysis, respectively was determined. B[e]P, a 
structural isomer of BP which has been reported to be weakly carcinogenic was also 
examined in parallel with BP (both in the absence and presence of CHL) to induce CYP1 
gene expression as well as cause DNA adduct formation. In addition, MCF-7, a malignantly 
transformed breast cell line was observed in parallel with NHMECs across different CHL 
treatments and concentrations to examine if their responses parallel those of normal cells and 
in turn whether they can be used as a surrogate to normal cells in studying carcinogenic 
stress. 
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3.0 MATERIALS AND METHODS 
 
Most experiments in this study were carried out on a panel of primary NHMECs 
developed from breast tissue discarded at reduction mammoplasty. In order to compare the 
responses of cancerous cells, a breast cancer cell line, MCF-7 was used in parallel with 
NHMEC(s) for some of the studies. Genome-wide changes in gene expression patterns were 
initially observed in a panel of 6 NHMECs. Subsequently, gene expression patterns of 
CYP1A1 and CYP1B1, two key BP metabolizing enzymes as well as the level of BP-DNA 
adducts was observed in a panel of 20 NHMECs. For studies on the comparison CYP1A1, 
CYP1B1 gene expression and the extent of DNA adducts on treatment of cells with BP or 
B[e]P, 2NHMECs (M98025 and M98015) were used. Studies for comparison of normal cells 
with malignantly transformed cells were carried out on a NHMEC strain (M00012) and the 
cancerous cell line MCF-7 over a range of CHL concentrations and treatments. An overview 
of the different experiments carried out in this study is shown in Table 2. 
 
3.1 Breast tissue 
Breast tissues from otherwise healthy women undergoing reduction mammoplasty 
were obtained from the Cooperative Human Tissue Network (CHTN) sponsored by the 
National Cancer Institute (NCI) and National Disease Registry Interchange (NDRI). 
Information on age, ethnicity of donors and a corresponding pathology report were obtained 
without personal identifiers. Since tissue samples were provided without personal identifiers 
the study was granted a waiver by the Human Studies Review Board at NIOSH. 
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3.2 Development of NHMEC strains 
NHMECs were isolated from the breast tissues by a process involving a combination 
of mechanical disruption, enzymatic digestion and filtration as described (Stampfer et al. 
1980) with slight modifications. Briefly, stromal and epithelial tissue masses (following 
removal of fat deposits (by dissection) were minced to 1-2 cm pieces, filled into 50 ml 
conical tubes up to 1/3rd the capacity and incubated overnight  at 370C, on a wave mixer with 
constant shaking with Tissue Digestion mix (Appendix). Following partial digestion the 
following day, the tubes were spun (250g, 10min in a swinging bucket centrifuge), the 
supernatant removed and the tissue pellet resuspended in fresh Tissue Digestion mix and 
incubated for another 24-48h to ensure complete tissue digestion. Complete tissue digestion 
was ascertained by observing for organoids (cell clumps) under 40X and 60X objectives of 
an Olympus IX70 Inverted Fluorescent light microscope. Completely digested pellets were 
pooled together (typically 4 tubes into1) and resuspended in 5 ml freezing media (Appendix). 
The resuspended pellets were then filtered through a 150 μm nylon filter and the flow 
through refiltered through a 90 μm nylon filter. The organoids retained on the 150 μm nylon 
filter were resuspended in a small volume of freezing media (Appendix) to constitute the 150 
μm ductal pool consisting mainly of a population of epithelial cells. Similarly, the organoids 
on the 90 μm filter were resuspended in a small volume of freezing media to constitute the 90 
μm fraction consisting of some small epithelial clumps. The 150 μm fraction, 90 μm fraction 
and the filtrate obtained after retention of the 90 μm fraction were all separately aliquoted to 
cryogenic vials frozen in isopropanol containers at -800C overnight and then archived in 
liquid nitrogen until needed. 
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3.3 Cell culture 
NHMECs were grown and sub-cultured up to passage 6. The 150 μm organoids were 
seeded with a sterile Pasteur pipette to collagen treated flasks, allowed to stand for about 5 
minutes and then supplemented with reconstituted serum-free mammary epithelial medium 
(MEBM; Clonetics™, Wakersville, MD) supplemented with manufacturer supplied 
Singlequots™ (gentamycin sulfate-amphothericin B, recombinant human epidermal growth 
factor, bovine insulin, bovine pituitary extract and hydrocortisone). Cell migration from the 
organoids was generally observed 24-48h after seeding. Cells were allowed to reach 60-70% 
confluency before they were sub-cultured. Cells were maintained in MEBM mammary 
epithelial medium at 370C, 5% CO2   and 95% relative humidity. NHMECs are adherent cells 
and were sub-cultured by trypsinization. Cells at 60-70% confluency were washed once with 
1X PBS following removal of media, incubated with 0.025% Trypsin-EDTA (Clonetics™, 
Wakersville, MD) at 2 ml Trypsin-EDTA/25cm2 growth area of the flask and then incubated 
at 370C for 2-3 min till ≥ 90% of the cells detached from the flask and appeared rounded 
when viewed under the microscope. At this stage the flask was gently rapped and the 
Trypsin-EDTA neutralized with Trypsin Neutralizing Solution (TNS) at 4 ml TNS/25cm2 
growth area of the flask and the detached cells were transferred to a 50 ml conical tube. The 
residual cells in the flask were collected by rinsing the flask with 1X PBS. The cells were 
centrifuged at 150g for 6min in a fixed angle centrifuge. The supernatant was aspirated, the 
cells washed with 1X PBS and cell pellet finally resuspended in MEBM mammary epithelial 
media. The suspended cells were then seeded into new flasks at 10,000 cells/cm2 and 
maintained in MEBM mammary epithelial medium. In this manner, cells were passaged up 
to passage 6.  MCF-7 cells were from ATCC and were grown, passaged and maintained in a 
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manner similar to the NHMECs. MCF-7 cells were grown and maintained in MCF-7 media 
(Appendix). 
 
3.4 Cell treatments 
All treatments were carried out on a uniform population of ~ 70% confluent cells at 
passage 6. The concentration of BP in all experiments was 4 μM. The concentration of CHL 
used was 5 μM for all experiments except for experiments involving a comparison of MCF-7 
cells with a NHMEC across a range of CHL concentrations. For these CHL dose response 
studies, CHL was used at a concentration of 2 μM, 3 μM, 4 μM, 8 μM and 16 μM. In all 
these experiments the concentration of BP and CHL used were decided based on preliminary 
cytotoxicity assays. For studies on comparison of BP and B[e]P the concentration of B[e]P 
used was also 4 μM in order to have a direct comparison with the effects of BP and was also 
dissolved in the same solvent as BP. BP was initially dissolved in acetone to obtain a 10 mM 
solution and subsequently diluted to 4 mM with absolute ethanol. The 4 mM solution was 
stored in amber vials shielded from light at -200C until needed. Nuclease free water served as 
the solvent for CHL. For treatment of MCF-7 and NHMECs with 5 μM CHL an initial stock 
solution of 5 mM was prepared. For the CHL dose response study, 2 mM, 3 mM, 4 mM, 8 
mM and 16 mM solutions were prepared. All CHL solutions were prepared fresh just before 
use and shielded from light. These stock solutions of BP and CHL respectively were later 
diluted 1000 fold in MEBM mammary epithelial medium just prior to treatment of cells to 
obtain the desired micromolar concentrations. Acetone: ethanol (2:3) at 1:1000 dilution used 
as a solvent for BP served as the vehicle control. All treatments were carried out in duplicate 
(n = 2). 
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The treatment protocol of 20 NHMECs and MCF-7 is detailed in Table 3. The treatment 
protocol for comparison of NHMECs on treatment with BP or B[e]P in the absence or 
presence of CHL is detailed in Table 4. The treatment protocol for the CHL dose response 
study comparing MCF-7 and a NHMEC (M00012) across a range of CHL concentrations is 
presented in Table 5. 
 
3.5 Expression analysis 
Analysis of genome-wide changes in gene expression patterns following exposure of 
NHMECs to BP in the absence or presence of CHL was carried out using microarrays. 
Subsequently, confirmation of gene expression patterns for a selected subset of genes which 
appeared altered on microarrays was carried out through real time polymerase chain reaction 
(RT-PCR). The magnitude and patterns of expression of CYP1A1 and CYP1B1, the main 
CYP isoforms known to be involved in the metabolism of BP/B[e]P was also carried out 
through RT-PCR. 
 
3.5.1 Microarray analysis 
Arrays 
Human genome U133A (HG-U133A) arrays containing 22,283 probe sets 
representing ~ 14,500 genes were purchased from Affymetrix (Affymetrix, Santa Clara, CA). 
The sequences used in the design of these arrays were derived from GenBank, dbEST, and 
RefSeq. These arrays form a part of the HG-U133 set which consists of 2 arrays (HG-U133A 
and HG-U133B) and altogether consists of almost 45,000 probe sets representing 
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approximately 33,000 well-substantiated human genes. HG-U133B mostly consists of ESTs 
and was therefore not used in this study.  
Target generation 
For microarray analysis due to considerations of cost and time involved only 3 
treatment groups (solvent control (SC), BP, and pre CHL + post co-treatment) were 
considered across 6 NHMEC strains (M98035, M99005, M98015, M98025, M99025 and 
M99016). 
Total RNA isolation 
Total RNA following treatment of cells was isolated using RNeasy kit (Qiagen, Valencia, 
CA) according to manufacturer’s instructions. Cells following treatment were washed with 
1X PBS, lysed in a chaotropic buffer containing guanidine isothiocyanate and homogenized 
in a spin column (Qiashredder) to shear high molecular weight DNA. The lysate containing 
total RNA was bound to a silica gel based membrane (RNeasy column) and the contaminants 
washed away using the manufacturer supplied wash buffers (RWE and RPE). Finally the 
bound total RNA was eluted out using RNAse free water.  
cDNA synthesis 
12 μg of total RNA (260:280 ratio >1.9 and clear, non-smearing rRNA bands on agarose gel) 
were used for synthesis of double stranded cDNA using T7-oligo(dT) promoter primer kit 
(Affymetrix, Santa Clara, CA) and SuperScript Double-Stranded cDNA Synthesis kit, 
(Invitrogen Life Technologies, Carlsbad, CA) as per manufacturer’s instructions. The 
generated double stranded cDNA was cleaned by phenol-chloroform extraction using Phase 
Lock Gels (PLG) and finally ethanol precipitated. The precipitated cDNA was dissolved in 
12.0 μl nuclease free water. 
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cRNA synthesis 
 A ‘one cycle’ target labeling assay was used for generation of labeled target. 6.0 μl of 
cleaned cDNA was used for the generation of biotin labeled complementary RNA (cRNA) 
target for hybridization on to HG-U133A arrays using the Gene Chip IVT Labeling Kit 
(Affymetrix, Santa Clara, CA). The generated cRNA was purified using RNeasy Kit (Qiagen, 
Valencia, CA) as per manufacturer’s protocol. The cleaned cRNA was subsequently 
quantified using a Beckman DU 7500 UV/VIS spectrophotometer (Beckman Coulter, Inc., 
Fullerton, CA) to determine the yield and quality of the generated cRNA. An adjusted cRNA 
yield was calculated using the formula below for further down-stream processing. 
Adjusted cRNA yield = RNAivt – (Total RNA) (y) 
RNAivt = amount of cRNA obtained following spectrophotometric analysis 
Total RNA = starting amount of total RNA used for cDNA synthesis 
y = fraction of the purified cDNA used for cRNA synthesis  
The cRNA was subsequently fragmented to 35-200nt bases (940C, 35 min) prior to 
hybridization on to the arrays by metal induced hydrolysis using a 5X RNA fragmentation 
buffer (Appendix). 
Hybridization 
15 μg of fragmented cRNA were used for hybridization on to ‘standard’ Hu-Gene 
133A arrays. The efficiency of target hybridization was assessed by incorporating pre-mixed, 
staggered concentrations of biotin labeled cRNA transcripts for three bacterial genes of the 
biotin synthesis pathway (bioB, bioC, bioD) and one bacteriophage gene for recombinase 
(cre) at staggered concentrations of 1.5 pM, 5 pM, 25 pM and 100 pM, respectively in a 
hybridization cocktail. A B2 oligo used as a positive hybridization control by the analysis 
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software to place a grid over the scanned image and demarcate the probe area was also 
spiked into the hybridization cocktail. The remaining components spiked into the 
hybridization cocktail included herring sperm DNA, acetylated BSA, hybridization buffer 
and DMSO (Affymetrix 2004). The cocktail was heated to 990C for 5 min prior to 
hybridization. The arrays with the hybridization cocktail were then incubated in a rotisserie 
oven at 450C for 16h with constant rotation (60 rpm). 
Washing, staining and scanning 
The hybridized arrays were subsequently washed and stained on the GeneChip 
Fluidics Station 400 (Affymetrix, Santa Clara, CA) using Eu-GE-W2v4 protocol of 
Microarray Suite (MAS) 5.0 (Affymetrix 2004). A signal amplification protocol consisting of 
first using streptavidin phycoerythroprotein (SAPE) followed by a biotinylated antibody to 
SAPE and then SAPE again was used as opposed to a single stain protocol. Following 
washing and staining the arrays were scanned with an argon-ion laser on the HP GeneArray 
2500 Scanner (Hewlett Packard, Palo Alto, CA). 
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Data analysis 
The scanning of arrays generated image files (.dat files) (Figure 6).   
 
Figure 6: Representative scanned 
image obtained following scanning 
of arrays. 
 
 
 
 
 
 
These .dat files were analyzed using MAS 5.0 (Affymetrix, Santa Clara, CA) to 
generate .cel files (with individual cell intensities), .chp files (with the analysis of cell 
intensities) and .rpt files (report files with an overview of various quality control parameters 
for each array/hybridization). Initially an ‘absolute analysis’ was conducted to compute 
absolute signal intensities of the SC as well as treated groups (BP and pre CHL + post co-
treatment). ‘Absolute analysis’ involves analysis of each of the individual arrays to determine 
the presence or absence of a particular transcript (Detection call), measure their relative 
abundance (Signal) and also provide a ‘Detection p-value’ evaluated against a user defined 
cut-off to determine the Detection call.  Two algorithms, a detection algorithm and a signal 
algorithm are employed to achieve this.  
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Subsequently, a ‘comparison analysis’ comparing the fold change (FC) of the treated 
groups over the SC (BP versus SC and pre CHL + co-treatment versus SC) was also 
conducted. A ‘change algorithm’ which defines the nature of change (increase, decrease or 
no change) in expression trends of the experimental array as compared to its counterpart 
baseline array and  another algorithm which provides a quantitative measure of the 
magnitude of change in terms of signal log ratio (SLR) are used for comparison analysis.  
In this study, only probe sets having a Present call (P) and a FC ~3.0 or greater (SLR 
≥1.5) for up- regulated genes and SLR≥-1.5 for down-regulated genes in both replicates in at 
least one of the 6 NHMECs were considered altered. Various quality control parameters such 
as background, noise, 3'/5' GAPDH and β-Actin ratios, and % Present calls (between 
replicates) were examined in the .rpt files.  
Graphical representation of all the altered genes were generated using Cluster and 
Tree View software (http://rana.lbl.gov/EisenSoftware.htm) using the average-linkage 
method (Sokal et al. 1958).   
To identify common patterns of gene expression patterns across cell strains following 
different treatments ‘coefficient of correlation clustering’ was conducted using Micro DB 3.0 
and Data Mining Tool (DMT) 3.0 (Affymetrix, Santa Clara, CA). In the ‘correlation of 
coefficient’ clustering, ‘seeding’,  a pre-clustering process involving initial grouping of a 
small subset of genes with similar expression patterns to generate a ‘seed’ is first carried out 
with a user specified correlation coefficient threshold. Subsequently, a correlation coefficient 
threshold to assign probe sets to a particular ‘seed’ in order to create a ‘cluster’ is also 
defined (Affymetrix 2001). In  this study, the correlation threshold of forming ‘seeds’ and 
assignment of genes to respective clusters were both set at 0.90. Clustering was carried out to 
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first find the genes common across all 6 cell strains on comparison of treated groups versus 
SC (BP versus SC and pre CHL + co versus SC). Only genes with a Present call (P) in both 
the replicates were used for the preliminary clustering. Subsequently, an unpaired, one-sided 
T test was carried out on above set of genes common to all 6 cell strains to find genes 
significantly altered due to respective treatment (p < 0.05) and also determine the direction of 
change (‘up’ or ‘down’). Gene expression ‘cluster maps’ were finally generated from the 
above subset of statistically significantly altered genes exhibiting particular expression 
pattern. 
Due to the importance of host immune responses in better tackling genotoxic insults, 
cross-talks between immune response genes altered by SLR ≥ 1.5 in at least one of the 6 
NHMECs  by the respective comparisons (BP versus SC and pre CHL + co versus SC) as 
well as any possible statistically significant associations of the altered genes with any of the 
presently well known and characterized biological pathways in GenMAPP, PharmGKB, 
KEGG and BioCarta was carried out using Pathway Studio v1.1 software (Ariadne 
Genomics, Rockville, MD) and ArrayXPath software 
(http://www.snubi.org/software/ArrayXPath), respectively.  
Pathway Studio relies on a proprietary ResNet database to query nearly 500,000+ 
functional relationships distilled from the entire PubMed and 43 full text journals to 
automatically extract information from scientific literature, and works with leading public 
and commercial databases of signaling and biochemical pathways, to construct cross-talks 
between the input genes/ proteins (http://www.ariadnegenomics.com). Initially, using 
Pathway Studio v1.1 all possible interactions of the altered immune response genes with all 
other processes, entities and proteins in the cell was deciphered. Later, ‘shortest path’ 
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interactions were sought. Finally, only direct interactions, if any, between genes altered by 
the respective treatments were deciphered.  
ArrayXPath is web-based software for mapping and visualization of microarray gene-
expression data in the context of integrated biological pathway resources. A total of 45 
pathways in GenMAPP pathways, 9 pathways PharmGKB pathways, 70 pathways in KEGG 
pathways and 346 pathways in Biocarta are queried by ArrayXPath to calculate associations 
of input genes with the respective pathways. A statistically significant association of the 
input gene(s) with alteration of the respective pathway is defined by a ‘p’ value 
(http://www.snubi.org/software/ArrayXPath). For genes involved in more than one pathway, 
a second p value (in this case designated as q value) accounts for the multiple-comparison. In 
this analysis, both ‘p’ and ‘q’ values were set at ≤ 0.05.   
 
3.5.2 RT-PCR 
Confirmation of gene expression on microarray was carried out through RT-PCR 
using ‘SYBR green chemistry’ for a selected sub-set of probes altered by SLR ≥ 1.5 in at 
least one of the 6 NHMEC strains. 1μg of total RNA isolated from 3 treatment groups (SC, 
BP and Pre CHL + post co-treatment) using RNeasy kit (Qiagen, Valencia, CA) was reverse 
transcribed to single stranded cDNA using Advantage RT PCR kit (BD Biosciences, Palo 
Alto, CA) as per manufacturer’s instructions 
Primers for these genes were designed using Primer Express v1.5 (PE Applied 
Biosystems, Foster City, CA), got synthesized from Sigma–Genosys (Wodlands, TX) and 
used at 50 pmol concentration of each primer in a 25 μl reaction mix with SYBR Green 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA). Quantitation was carried 
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out using a standard 96-well block on the 7900HT Fast Real-Time PCR System preloaded 
SDS software v2.2.2 (Applied Biosystems, Foster City, CA). Each sample was assayed in 
duplicate and their expression normalized to that of GAPDH using the 2-∆∆CT method (Livak 
et al. 2001). The specificity of the generated product was confirmed by looking for a single 
specific product on ‘Amplify’ software v1.2β (University of Wisconsin, Genetics, Madison) 
prior to RT-PCR as well as going in for dissociation curves at the end of the run. 
CYP1A1 and CYP1B1 quantitation across the panel of 20 NHMECs and MCF-7 cells 
for all treatment groups was carried out using ‘Taqman chemistry’. The expression analysis 
across the 20 NHMECs (on treatment with BP in the absence or presence of CHL as detailed 
in Table 3) and 2 NHMECs (on treatment with BP/B[e]P in the absence or presence of CHL 
as detailed in Table 4) were carried out on the ABI7700 Sequence Detection System (PE 
Applied Biosystems, Foster City, CA). CYP1A1 and CYP1B1 quantitation in MCF-7 cells 
and M00012 across different CHL concentrations (as detailed in Table 5) and in MCF-7 cells 
across different CHL treatments (as detailed in Table 3) was carried out on the ABI 7900HT 
Fast Real-Time PCR System (PE Applied Biosystems, Foster City, CA) using ‘Taqman 
chemistry’. 1.0 μg of total RNA (RNeasy kit; Qiagen, Valencia, CA) from each of the treated 
groups was used for cDNA synthesis. Single stranded cDNA (Advantage RT PCR kit; BD 
Biosciences, Palo Alto, CA) was used as template in a 50µl reaction mix consisting of 2X 
Taqman Universal PCR Master Mix and Taqman® Gene Expression Assay primers and 
probes for CYP1A1 (Hs00153120_ml) or CYP1B1 (Hs00164383_ml) (Applied Biosystems, 
Foster City, CA). Each sample was assayed in duplicate and their expression normalized to 
that of GAPDH (Hs99999905_ml; Applied Biosystems, Foster City, CA) using the 2-∆∆CT 
method (Livak et al. 2001). 
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3.6 Adduct analysis 
BP-DNA adducts formed on treatment of 20 NHMECs as well as MCF-7 cells with 
BP in the absence or presence of CHL was determined through a chemiluminiscence 
immunoassay (CIA). B[e]P-DNA adducts formed on treatment of 2 NHMEC strains with 
B[e]P in the absence or presence of CHL was analyzed through synchronous fluorescence 
spectrometry (SFS). 
 
3.6.1 DNA extraction 
DNA was extracted using a non-organic extraction protocol (Laird et al. 1991). 
Following treatment, cells were washed with 1X PBS, incubated in a lysis buffer (100 mM 
Tris pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl and 100 µg/ml Proteinase K) at 370C 
for 3h and the DNA precipitated with an equal volume of isopropanol. The precipitated DNA 
was washed twice with 70% ethanol and then dissolved in nuclease free water. 
 
3.6.2 BP-DNA (BPdG) adduct analysis 
BPdG adducts were measured by a chemiluminiscence immunoassay (CIA) using 
antiserum elicited against DNA modified with (±)-7β,8α, dihydroxy 9α,10α-epoxy-7,8,9,10-
tetrahydrobenzo[α]pyrene (BPDE) (8). Briefly, sonicated (20s, 20% amplitude, Ultrasonic 
Processor, Sonics & Materials, Inc, Newton, CT) and heat denatured (950C, 4min and then 
cooled on ice) sample DNA or serially diluted standard BPDE-DNA (1.0 BPdG adduct/106 
nucleotides) was mixed with an equal volume of  rabbit anti-BPDE antiserum (1:3000000 in 
0.25% casein prepared in phosphate buffered saline containing 0.05% Tween-20 (PBST)), 
incubated at 370C for 15 min and added to wells of 96-well high binding LIA microtiter 
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plates (Greiner Labortechnik, FRG) coated with highly modified BPDE-DNA or calf thymus 
DNA. These plates were prepared by coating with 100 pg of highly modified, sonicated 
BPDE-DNA (0.33% modified) or non-adducted calf thymus DNA in 0.1ml Reactibind 
solution (Pierce Biotechnology, Inc., Rockford, IL) for 48h following which they were 
washed with PBST containing 0.05% sodium azide and stored at -200C until used. The plates 
along with the sample or standard DNA were incubated at 370C for 90 min, washed with 
PBST, incubated with streptavidin alkaline phosphatase (Avidx-AP: 1:5000, 60 min; Applied 
Biosystems, Foster City, CA) prepared in 0.25% casein, washed again with PBST and Tris 
buffer (20 mM Tris, 1mM MgCl2, pH 9.5) before finally incubating with CDP-Star solution 
containing Emerald II enhancer (Applied Biosystems, Foster City, CA). The plates were 
incubated overnight at 40C and the luminescence measured at 542 nm on TR717 Microplate 
Luminometer (Applied Biosystems, Foster City, CA) on the following day after equilibration 
of the plates to room temperature. All samples were assayed in triplicate experimental wells 
and two separate CIAs.  
 
3.6.3 B[e]P-DNA adduct analysis 
DNA extracted using a non-organic protocol as detailed above were assayed for 
B[e]P-DNA adducts using synchronous fluorescence spectrometry (SFS). 100 μg of DNA 
was acid hydrolyzed (900C, 3h), extracted three times with equal volumes of water-saturated 
isoamyl alcohol and then resuspended in 600 μl HPLC grade water. Benzo(a)pyrene-r-7, t-8, 
c-9, t-10-tetrahydrotetrol (+/1) was used to generate a standard curve. Synchronous spectra 
were obtained by driving the excitation and emission monochromators simultaneously with a 
wavelength difference of 34 nm.  Fluorescent emission was obtained at emission wavelength 
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of 380 nm (345 nm excitation wavelength). All measurements were carried out on a Perkin 
Elmer LS50B spectrophotometer (Perkin Elmer Corp., Rockville, MD) loaded with WinLab 
FL software. 
 
3.7 Statistical correlations 
Pearson correlation coefficients between the extent of expression of CYP1A1 and 
CYP1B1 on gene-chip (GC) versus RT-PCR as well as correlation coefficients between 
CYP1A1 and CYP1B1 expression and levels of carcinogen-DNA adducts on treatment of 
NHMECs or MCF-7 cells with BP or B[e]P in the absence or presence of CHL were 
determined using Excel (Saunders et al. 1994). Positive values indicate an increase in the 
value of the dependent variable with a corresponding increase in the independent variable 
and vice versa.  
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 Table 2: Details of different experiments carried out in the present study  
Experiment Number and 
type of cell 
strains used 
Cell strains used Treatments 
used 
1. Microarray 
analysis 
6 NHMECs 
M98035, M99005, M98015, 
M98025, M99025, M99016  
1, 2 and 5 as 
detailed in 
Table 3 
2. RT-PCR and DNA 
adduct analysis 
   
a. On treatment with 
BP ± CHL 
20 NHMECs M98026, M98019, M98014, 
M98011, M99021, M99006, 
M99025, M0004, M98025, 
M98035, M99005, M99003, 
M00012, M99004, M98016, 
M99015, M98030, M98015, 
M98013, M99016 
1, 2, 3, 4  
and 5 as 
detailed in 
Table 3 
b. On treatment with 
BP or B[e]P ± CHL 
2 NHMECs M98015 and M98025 1, 2, 3, 4  
and 5 as 
detailed in 
Table 4 
c. On comparison of 
a NHMEC versus a 
cancerous cell line 
on treatment with BP 
± CHL 
20 NHMECs 
and MCF-7  
The same 20 NHMECs 
mentioned above and MCF-7 
(cancerous cell line) 
1, 2, 3, 4  
and 5 as 
detailed in 
Table 3 
d. On treatment with 
BP ± a range of CHL 
concentrations 
1 NHMEC 
strain and 
MCF-7 
M00012 (NHMEC strain) 
and MCF-7 (cancerous cell 
line) 
1, 2, 3, 4, 5, 
6 and 7 as 
detailed in 
Table 5 
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Table 3: NHMECs and MCF-7 cells treatment protocol 
 
Treatment Treatment protocol 
1. Control vehicle 
(SC) 
- Acetone: ethanol (1:1000)-24h 
2. BP alone (BP) - BP (4 μM)-24h 
3. CHL + BP 
 (co-treatment) 
- [CHL (5 μM) + BP (4 μM)]-24h 
4. Pre CHL + post 
BP treatment 
CHL (5 μM)-24h      + BP (4 μM)-24h 
5. Pre CHL + post 
co-treatment 
CHL (5 μM)-24h      + [CHL (5 μM) + BP (4 μM)]-24h 
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Table 4: Treatment protocol for the comparison of BP and B[e]P across 2 NHMECs 
(M98015 and M98025)  
 
Treatment Treatment protocol 
1. Control vehicle (SC) - Acetone: ethanol (1:1000)-24h 
2. BP or B[e]P alone  - BP or B[e]P (4 μM)-24h 
3. CHL + BP or B[e]P 
(co-treatment) 
- [CHL (5 μM) + BP or B[e]P(4 
μM)]-24h 
4. Pre CHL + post BP 
or B[e]P treatment 
CHL (5 μM)-24h      + BP or B[e]P (4 μM)-24h 
5. Pre CHL + post BP 
co-treatment or post 
B[e]P co-treatment 
CHL (5 μM)-24h      + [CHL (5 μM) + BP or B[e]P (4 
μM)]-24h 
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Table 5: Treatment protocol for the CHL dose response study comparing MCF-7 and 
an NHMEC (M00012) across a range of CHL concentrations 
 
Treatment Treatment protocol 
1. Control vehicle (SC) - Acetone: ethanol (1:1000)-24h 
2. BP alone (BP) - BP (4 μM)-24h 
3. Pre 2 μM CHL + 
post BP + 2 μM 
CHL co-treatment) 
CHL (2 μM)-24h      + [CHL (2 μM) + BP (4 μM)]-24h 
4. Pre 3 μM CHL + 
post BP + 3 μM 
CHL (co-treatment) 
CHL (3 μM)-24h      + [CHL (3 μM) + BP (4 μM)]-24h 
5. Pre 4 μM CHL + 
post BP + 4 μM 
CHL (co-treatment) 
CHL (4 μM)-24h      + [CHL (4 μM) + BP (4 μM)]-24h 
6. 8 μM CHL + post 
BP + 8 μM CHL 
(co-treatment) 
CHL (8 μM)-24h      + [CHL (8 μM) + BP (4 μM)]-24h 
7. Pre 16 μM CHL + 
post BP + 16 μM 
CHL (co-treatment) 
CHL (16 μM)-24h     + [CHL (16 μM) + BP (4 μM)]-24h 
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4.0 RESULTS 
 
4.1 Gene expression by microarray 
 The expression of a multitude of genes involved in diverse cellular functions was 
altered by BP. The expression patterns of all the 22,283 probe sets (14,500 genes) on Hu-
Gene 133A array in each of the 6 NHMEC strains on treatment with BP alone or in the 
presence of CHL (pre CHL + post co-treatment) are presented in Figure 7. The figure 
depicts a plot of the signal from each of the 22,283 probe sets for each of the respective 
treatment replicates versus the corresponding FC for those probe sets. It provides an 
overview of the scatter of expression patterns across cell strains and treatments. Each cell 
strain exhibited similar expression patterns for some of the probe sets yet unique expression 
patterns for others. The scatter plot also shows that for some probe sets while the signal 
may be low the overall FC compared to SC could be high and vice versa. While the 
expression of majority of the genes across most cell strains exhibited variation within 2-3 
fold, there clearly appeared to be outliers which were treatment as well as cell strain 
specific. Of these probe sets, only those altered by a FC of ~3.0 (SLR≥ 1.5) in both the 
replicates upon comparison analysis of a respective treatment versus SC were considered 
altered. A complete list of all genes altered by SLR ≥ 1.5 in at least one of the 6 NHMECs 
on comparison of BP treated as well as pre CHL + post co-treated cells versus SC can be 
found in Tables A, B, C , D and E at (http://www.cdc.gov/niosh/ext-supp-
mat/MTP/index.htm). Genes of the biotin synthesis pathway, bioB, bioC, bioD and the 
bacteriophage gene, cre spiked in the hybridized cocktail as hybridization controls were all 
detected on the arrays with signals in increasing order, as expected. Human GAPDH and 
Actin, house keeping genes were also detected. The average background, noise, percentage  
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M99005
M98015
M98025
M99025
M99016
BP versus control vehicle Pre CHL + co-treated versus control vehicle 
M98035
Signal Signal 
Figure 7: ‘Fold change’ scatter plots showing expression patterns of all the 22,283 probe sets on Hu-
Gene133A arrays on comparison of treated groups versus control vehicle. More details in the text. 63 
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of genes present, absent and average signal intensities were also examined for each of the 
arrays. 
A total of 49 genes (0.38%) were altered in at least one of the 6 NHMEC strains on 
comparison of BP treated cells with SC when analyzed by MAS 5.0. Of these 43 were up-
regulated and only 6 were down-regulated. Only CYP1B1 exhibited consistent up-
regulation by SLR ≥ 1.5 in all 6 cell strains. ALDH1A3 (probe ID 222168_at) showed up-
regulation in 4 cell strains. All other genes were up-regulated in less than 4 cell strains. All 
down-regulated genes were from only one cell strain, M99016 and no gene was 
consistently down–regulated by SLR≥ 1.5 in all the cell strains. IL1B and SECTM1 were 
immune response genes consistently up-regulated by BP in most individuals with M99016 
exhibiting the greatest expression with SLR ≥ 1.5. Both the above genes also exhibited the 
greatest expression in M99016 on pre-treatment with CHL followed by co-treatment and 
were, therefore, represented in the list of genes up-regulated by BP as well as pre CHL + 
post co-treatment. Overall, genes altered included those involved with xenobiotic 
metabolism, cell signaling, cell motility, cell proliferation, cellular transcription, 
metabolism, immune responses and other processes.  
A total of 125 genes (0.86%) were altered in at least one of the 6 NHMEC strains 
on comparison of pre CHL + post co-treated cells with SC when analyzed by MAS 5.0. Of 
these 103 were up-regulated and 22 down-regulated. Again, only CYP1B1 was consistently 
up-regulated by SLR ≥ 1.5 in all but one cell strain. No gene was consistently down-
regulated by SLR ≥ 1.5 in all cell strains. Gene categories modulated included mainly those 
altered by BP treatment in addition to genes involved in cell cycle control, apoptosis, DNA 
repair and various other cellular processes such as neurogenesis, gene regulation, and 
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hormonal metabolism. A graphical display of all the altered genes generated using Cluster 
and Tree View (http://rana.lbl.gov/EisenSoftware.htm) according to the average linkage 
method (Sokal et al. 1958) is presented in Figure 8. 
As per DMT 3.0 analysis a total of 5 different expression clusters were obtained on 
clustering of genes altered by comparison of treated groups versus SC (Figure 9). One 
cluster each was generated on clustering of genes significantly up-regulated and down-
regulated by BP as well as genes significantly down-regulated by pre treatment with CHL 
followed by co-treatment. However, two different expression clusters were generated for 
genes significantly up-regulated by pre CHL + post co-treatment. In all cases, the 
correlation of the altered genes belonging to the respective cluster pattern was 0.99. A 
complete list of all the genes following the respective cluster patterns can be found in 
Tables G, H, I and J at (http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm). More 
details of the characteristics of the genes used for the ‘correlation coefficient’ clustering are 
displayed in Table 6. 
Given the importance of immune responses in parallel with other cellular 
mechanisms such as detoxication and repair mechanisms to combat toxic stress, immune 
response genes altered by SLR ≥ 1.5 in at least one of the 6 NHMECs in both the replicates 
upon comparison analysis of a respective treatment versus SC by MAS 5.0 were analyzed 
separately. Any interactions and cross-talks between the significantly altered immune 
response genes as well as other cellular proteins were analyzed. A total of only 5 immune 
response genes were altered by SLR ≥ 1.5 on comparison of BP treated cells versus SC of 
which 4 were up-regulated and only 1 was down-regulated by SLR ≥ 1.5 in at least one of 
the 6 NHMEC strains. The expression of 24 genes was altered by the synergistic  
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Figure 8: Graphical display (generated using Cluster and Tree View software) of all genes 
altered by SLR ≥ 1.5 on Hu-Gene 133A arrays in at least one of the 6 NHMECs on 
treatment of cells with BP or pre CHL + co-treatment. A total of 49 genes were altered (up 
or down regulated) on treatment with BP alone and 125 on pre treatment with CHL 
followed by co-treatment. Though the gene names are not decipherable in the figure above 
due to the number of genes involved, a complete listing of all the above genes along with 
their corresponding FCs can be found at (http://www.cdc.gov/niosh/ext-supp-
mat/MTP/index.htm) [Tables A, B, C, D]. 
 
Genes altered (SLR 
≥1.5) by pre CHL + 
co-treatment versus 
control vehicle 
Genes altered (SLR 
≥1.5) by BP versus 
control vehicle 
BP versus 
control vehicle 
Pre CHL + co- 
treatment versus 
control vehicle 
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 Genes altered by BP treatment 
Clusters 3(A) and 3(B): Pre CHL + co-treatment versus SC - up-regulated genes                     
Cluster 4: Pre CHL + co-treatment versus 
SC - down-regulated genes                             
Genes altered by Pre CHL + co-treatment 
Cluster 2: BP versus SC - down-regulated 
genes                                  
Figure 9: Correlation coefficient gene-expression 
clusters created from genes altered significantly in all 6 
donors on comparison of the respective treated groups 
versus solvent control (SC). Each point on each cluster 
was calculated using the average signal generated by 
the respective treatment: 1= SC, 2 = BP alone and 3 = 
pre CHL + co-treatment. The number of genes/probes 
displaying the respective cluster pattern are shown in 
parenthesis besides each cluster. The correlation 
coefficient (CC) of the genes following the respective 
cluster pattern is shown below each cluster. Details 
about the exact genes in each cluster following the 
respective cluster pattern can be found at 
(http://www.cdc.gov/niosh/ext-supp-
mat/MTP/index.htm) [Tables G, H, I and J]. 
A B 
1
2
3
1
1
1
2
2
2
3
3
3
1
2
3
Cluster 1: BP versus SC - up-regulated 
genes    
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Table 6: Table representing the number and characteristics of the probe sets used to 
generate the clusters displayed in Figure 9 
 
Comparison 
Number of 
probes common 
to all 6 NHMECs 
altered by 
respective 
comparison 
Number of probes 
common to all 6 
NHMECs altered 
significantly (p< 
0.05) by the 
respective 
comparison 
Number of 
significantly 
altered probes (p< 
0.05) exhibiting 
common clustering 
pattern  
Correlation 
coefficient 
of probes 
belonging 
to 
respective 
cluster 
BP versus control vehicle 
(up-regulated) 
 
391 106 71 
 
0.99 
 
BP versus control vehicle 
(down-regulated) 
 
383 134 96 0.93 
Pre CHL + co- treatment 
versus control vehicle  
(up-regulated) 
 
228 46 39, 3 0.99, 0.99 
Pre CHL + co- treatment 
versus control vehicle 
(down-regulated) 
 
232 41 40 0.99 
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interaction of BP and CHL coming together in a pre CHL + co-treatment of which 15 genes 
were up-regulated and 9 were down-regulated by SLR ≥ 1.5. The expression of IL1B and 
SECTM1 were consistently up-regulated by BP in most individuals with M99016 
exhibiting the greatest expression with SLR ≥ 1.5. Both genes also exhibited the greatest 
expression in M99016 on pre-treatment with CHL followed by co-treatment. A graphical 
display of all altered immune genes was also generated using Cluster and Tree View 
according to the average linkage method (Sokal et al. 1958) and is presented in Figure 10.  
Altered immune response genes were analyzed for cross-talks/signal transduction 
between themselves and with other cellular entities as well as other cellular pathways. 
Though the altered genes are fed as gene names to Pathway Studio, the software takes them 
as corresponding proteins while constructing interactions between the input entities as well 
as all other entities within the cell. When genes altered by BP treatment versus SC were 
queried for all possible interactions with all other molecules and processes within the cell 
using Pathway Studio, a total of 2248 relationships/interactions involving 1485 entities 
including proteins, small molecules, and various functional classes of molecules, 
complexes and cellular processes were found to be involved. When only ‘shortest cross-
talk’ interactions were considered for the above genes only 60 relationships were found 
between 249 entities. However, there were no direct interactions between the 5 altered 
genes (Figure 11). More details about the various interactions among the immune response 
genes altered by comparison of BP versus SC can be found at 
(http://www.cdc.gov/niosh/ext-supp-mat/IR_Genes/index.htm) (IR-BP genes).  
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Figure 10: Graphical representation (generated using Cluster and Tree View software)  
of all immune response genes altered by SLR ≥ 1.5 on Hu-Gene 133A arrays in at least one 
of the 6 NHMECs on treatment with BP or pre CHL + co-treatment. A complete listing of 
all the above immune response genes along with their corresponding FCs can be found at 
(http://www.cdc.gov/niosh/ext-supp-mat/IR_Genes/index.htm) [IR genes with FC table] 
 
 
BP versus 
control 
vehicle 
Pre CHL + co 
versus control 
vehicle 
BP versus control 
vehicle-up-regulated 
BP versus control vehicle- 
down-regulated genes 
Pre CHL + co treatment 
versus control vehicle- 
up-regulated genes 
Pre CHL + co-treatment 
versus control vehicle- 
down-regulated genes 
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Figure 11: Five immune response genes were altered by SLR ≥ 1.5 on Hu-Gene 133A 
arrays in at least one of the 6 NHMECs on exposure to BP alone. These five immune 
response genes were queried for any direct interactions between themselves using Pathway 
Studio software. The software takes the input genes as the corresponding proteins while 
trying to construct any interactions between the respective members. In this case, no direct 
interactions were observed between any of the input entities. The different immune 
response proteins are shown according to their respective cellular location.  
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Genes altered by pre CHL + post co-treatment were found to exhibit 5782 
interactions among and between 2299 entities within the cell. Of these 379 entities 
including the altered genes were found to be involved in 704 ‘shortest cross-talk’ 
interactions. However, there were only 51 direct interactions between the altered genes 
(Figure 12). More details about the various interactions among the immune response genes 
altered by comparison of pre CHL + post co-treatment can be found at 
(http://www.cdc.gov/niosh/ext-supp-mat/IR_Genes/index.htm) (IR-CHL genes). It must be 
mentioned that since Pathway Studio relies largely on PubMed to construct interactions and 
since the content of PubMed is highly ‘dynamic’, the nature and number of interactions 
between the same input members and all other cellular entities are likely to vary with time. 
Using ArrayXPath software, 2 (IL1B and MAL) out of the 5 genes altered by BP 
were found to have a statistically significant association (p < 0.05) with 5 Biocarta 
pathways (Table 7). A total of 45 pathways in GenMAPP, 9 pathways in PharmGKB, 70 
pathways in KEGG pathways and 346 Biocarta pathways were queried by Array X to 
obtain the above associations. A total of 2 (CD80 and CD86) out of 23 genes altered by pre 
CHL +  post co-treatment were involved in one GenMAPP pathway and 6 genes (SLP1, 
IL8, IL1B, IL1RN, CD80 and CD86) were found to be involved in 13 Biocarta pathways 
(Table 8).  
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Figure 12: Twenty four immune response genes were altered by SLR ≥ 1.5 on Hu-Gene 
133A arrays in at least one of the 6 NHMECs on treatment with pre CHL + co-treatment. 
IL8 was up-regulated by SLR ≥ 1.5 in some of the NHMECs but down-regulated by SLR ≥ 
1.5 in the others and therefore represented in common in list of up-regulated and down-
regulated genes. These twenty four immune response genes were queried for any direct 
interactions between themselves using Pathway Studio software. The software takes the 
input genes as the corresponding proteins while trying to construct any interactions 
between the respective members. Fifty one direct interactions were observed between the 
input entities. The different immune response proteins are shown according to their 
respective cellular location. Genes with no direct interactions between themselves are 
shown as separate entities. 
 
Interaction legend 
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Table 7: Pathways in which immune response (IR) genes altered by SLR ≥1.5 on Hu-
Gene133A arrays on comparison of BP treated cells versus control vehicle are involved. 
A total of 5 IR genes were altered by SLR ≥1.5 of which 2 (40%) (IL1B, MAL) were found 
to possess a statistically significant association (p≤ 0.05) with the above pathways. For 
genes involved in more than one pathway, a q value (q≤ 0.05, equivalent to p value) 
accounts for the multiple-comparison.  
 
Pathway  Identified node p-value q-value 
BioCarta//Hs_IL 5 Signaling Pathway       1/8 (19) 0.0101 0.0154 
BioCarta//Hs_NFkB activation by Nontypeable Hemophilus 
influenzae       1/24 (43) 0.0300 0.0230 
BioCarta//Hs_Signal transduction through IL1R       1/30 (41) 0.0374 0.0230 
BioCarta//Hs_Role of MAL in Rho-Mediated Activation of SRF      1/19 (26) 0.0238 0.0230 
BioCarta//Hs_Msp/Ron Receptor Signaling Pathway       1/6 (27) 0.0075 0.0232 
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   Table 8: Pathways in which immune response (IR) genes altered by SLR ≥1.5 on Hu-
Gene133A arrays on comparison of CHL treated cells (pre CHL + co-treated) versus 
control vehicle are involved. A total of 23 IR genes were altered by SLR ≥1.5 of which 6 
(26%) (SLP1, IL8, IL1B, IL1RN, CD80 and CD86) were found to possess a statistically 
significant association (p≤ 0.05) with the above pathways. For genes involved in more 
than one pathway, a q value (q≤ 0.05, equivalent to p value) accounts for the multiple-
comparison.  
 
Pathway  Identified node p-value q-value 
BioCarta//Hs_Proepithelin Conversion to Epithelin and Wound 
Repair Control       2/6 (40) 0.0002 0.0018 
BioCarta//Hs_The Co-Stimulatory Signal During T-cell 
Activation       2/16 (40) 0.0014 0.0072 
BioCarta//Hs_NFkB activation by Nontypeable Hemophilus 
influenzae       2/24 (43) 0.0032 0.0110 
BioCarta//Hs_Signal transduction through IL1R       2/30 (41) 0.0049 0.0128 
BioCarta//Hs_Free Radical Induced Apoptosis       1/10 (11) 0.0373 0.0430 
BioCarta//Hs_IL 5 Signaling Pathway       1/8 (19) 0.0299 0.0430 
BioCarta//Hs_Msp/Ron Receptor Signaling Pathway       1/6 (27) 0.0225 0.0430 
BioCarta//Hs_B Lymphocyte Cell Surface Molecules       1/9 (10) 0.0336 0.0430 
BioCarta//Hs_Antigen Dependent B Cell Activation       1/10 (24) 0.0373 0.0430 
BioCarta//Hs_IL 17 Signaling Pathway       1/15 (16) 0.0554 0.0443 
BioCarta//Hs_Regulation of hematopoiesis by cytokines       1/15 (41) 0.0554 0.0443 
BioCarta//Hs_Adhesion and Diapedesis of Lymphocytes       1/14 (47) 0.0518 0.0443 
BioCarta//Hs_Adhesion and Diapedesis of Granulocytes      1/15 (49) 0.0554 0.0443 
BioCarta//Hs_Cells and Molecules involved in local acute 
inflammatory response       1/17 (19) 0.0626 0.0459 
BioCarta//Hs_Th1/Th2 Differentiation       1/18 (88) 0.0662 0.0459 
BioCarta//Hs_Cytokine Network       1/22 (103) 0.0804 0.0522 
BioCarta//Hs_Cytokines and Inflammatory Response       1/27 (78) 0.0979 0.0598 
GenMapp//Hs_Inflammatory_Response_Pathway        2/29(29) 0.0004 0.0004 
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4.2 RT-PCR 
4.2.1 Confirmation of gene expression on microarrays 
Confirmation of gene expression patterns on microarrays was carried out through 
RT-PCR for a selected subset 24 genes altered by SLR≥ 1.5 in both replicates in at least 
one of the 6 NHMECs. Of these, 7 were immune response genes. The results of RT-PCR 
confirmation are presented in Tables 9A, 9B and 10. A more extensive version of Tables 
9A and 9B can be found in Table E and Table F, respectively at 
(http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm). For genes altered by BP, there 
was a very good correlation of FC as measured by GC and RT-PCR for all genes except for 
CALB1 and SECTM1 which exhibited only a moderate correlation and MERTK which 
exhibited a very poor correlation. A very good correlation of FC between GC and RT-PCR 
was also observed for all genes altered on pre-treatment with CHL followed by co-
treatment except for AKR1C2, DHRS3 and MCM5 which exhibited only a moderate 
correlation.  
As for the immune response genes there was a good correlation for some genes 
while the remaining correlated moderately to poorly (Table 10). Upon BP treatment there 
was a good correlation for 1L1B and CXCL2, a moderate correlation for PI3 but a poor 
correlation for the remaining genes (SECTM1, IL1RN, CD86 and MX1). However, more 
genes had a better correlation on pre CHL + co-treatment. IL1RN and PI3 also exhibited a 
good correlation of expression on GC versus RT-PCR apart from 1L1B and CXCL2 while 
CD86 and MX1 exhibited a moderate correlation. 
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Table 9A: Correlation of fold change (FC) on Hu-Gene 133A arrays/gene-chip (GC) and RT-PCR for a partial list of genes altered 
by SLR≥1.5 in at least one of the 6 NHMECs when treated with BP alone. A more extensive version of this table can be found at 
(http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm) [Table E]. 
 
Correlation (r)
Gene Probe ID Accession no. GC-RT
BP alone
CYP1B1 202437_s_at NM_000104 6.76 ± 0.99 10.14 ± 0.46 3.62 ± 0.53 7.61 ± 0.32 11.72 ± 0.57 32.10 ± 0.85 5.55 ± 1.35 7.52 ± 2.41 13.46 ± 0.66 21.58 ± 2.18 5.89 ± 0.86 9.28 ± 2.35 0.87
CYP1A1 205749_at NM_000499 1.68 ± 0.87 10.48 ± 1.47 1.65 ± 0.92 14.50 ± 0.79 11.34 ± 1.11 47.62 ± 2.64 8.59 ± 0.84 15.92 ± 2.62 1.32 ± 0.13 9.83 ± 0.99 9.21 ± 0.90 95.29 ± 5.83 0.67
ALDH1A3 222168_at NM_000693 3.23 ± 1.09 4.54 ± 0.44 3.03 ± 0.00 3.44 ± 0.53 14.43 ± 0.71 7.74 ± 0.59 -1.96 ± 5.80 3.14 ± 0.67 1.44 ± 0.42 3.84 ± 2.98 16.65 ± 2.44 14.42 ± 2.49 0.90
MERTK 206028_s_at NM_006343 7.25 ± 1.06 0.67 ± 0.47 1.57 ± 0.60 1.59 ± 0.64 1.57 ± 0.60 2.06 ± 0.33 0.27 ± 2.25 1.94 ± 1.88 1.42 ± 0.14 NA ±  - -2.82 ± 5.86 0.92 ± 0.27 -0.30  
CALB1 205625_s_at NM_004929 -1.37 ± 3.35 0.48 ± 0.09 -1.27 ± 4.26 0.90 ± 0.04 -1.42 ± 0.14 0.53 ± 0.05 0.06 ± 2.55 0.38 ± 0.09 3.26 ± 0.32 1.68 ± 0.62 -1.80 ± 4.42 0.83 ± 1.17 0.20
SECTM1 213716_s_at NM_003004 3.06 ± 0.60 3.07 ± 0.31 2.17 ± 0.93 4.28 ± 0.45 2.65 ± 0.26 7.48 ± 2.33 2.38 ± 0.12 6.55 ± 0.51 1.52 ± 0.15 5.97 ± 0.86 3.41 ± 0.83 10.94 ± 0.83 0.39
SGK 201739_at NM_005627 -1.46 ± 0.07 0.61 ± 0.12 -1.41 ± 0.00 0.78 ± 0.16 -1.41 ± 0.00 0.62 ± 0.11 -1.94 ± 0.28 0.54 ± 0.02 -1.43 ± 0.28 0.86 ± 0.05 -2.93 ± 0.14 0.37 ± 0.04 0.83
CTGF 209101_at NM_001901 -2.64 ± 0.00 0.48 ± 0.09 -1.63 ± 0.16 0.90 ± 0.04 -1.63 ± 0.16 0.53 ± 0.05 -2.81 ± 0.95 0.38 ± 0.09 -1.43 ± 0.28 1.05 ± 0.02 -3.56 ± 1.03 0.30 ± 0.13 0.85
PPP1R3C 204284_at NM_005398 -1.47 ± 0.22 0.64 ± 0.08 1.11 ± 0.05 0.82 ± 0.08 -1.87 ± 0.00 0.52 ± 0.01 -1.28 ± 0.19 0.61 ± 0.14 -1.83 ± 0.44 0.33 ± 0.03 -3.26 ± 0.32 0.24 ± 0.06 0.89
NA= no amplification by RT-PCR
  = only 5 donors with amplification considered for correlation analysis
GC RT-PCR GC RT-PCR GC RT-PCR GC RT-PCR GC RT-PCR GC RT-PCR
BP alone vs vehicle control ( avg. FC ± SD)
 6 (M99016)4 (M98025)  5 (M99025) 1 (M98035)  2 (M99005) 3 (M98015)
 
 
 
Table 9B: Correlation of fold change (FC) on Hu-Gene 133A arrays/gene-chip (GC) and RT-PCR for a partial list of genes altered 
by SLR≥1.5 in at least one of the 6 NHMECs when treated with pre-CHL followed by co-treatment. A more extensive version of 
this table can be found at (http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm) [Table F]. 
 
Correlation (r)
Gene Probe ID Accession no. GC-RT
PreCHL + co
AKR1C2 211653_x_at NM_001354 3.04 ± 0.30 1.62 ± 0.13 1.74 ± 0.00 1.82 ± 0.06 2.07 ± 0.10 2.00 ± 0.16 5.10 ± 0.25 2.39 ± 0.08 2.08 ± 0.30 2.25 ± 0.22 2.22 ± 0.11 1.76 ± 0.48 0.50
CLDN4 201428_at NM_001305 7.03 ± 1.37 4.87 ± 0.39 -6.06 ± 0.00 0.13 ± 0.01 1.88 ± 0.37 1.43 ± 0.08 15.13 ± 6.46 3.71 ± 0.14 -0.31 ± 2.59 0.46 ± 0.04 3.62 ± 0.53 0.35 ± 0.04 0.76
DHRS3 202481_at NM_004753 1.80 ± 0.09 1.52 ± 0.17 -1.19 ± 0.06 0.96 ± 0.03 1.76 ± 0.34 2.17 ± 0.94 3.26 ± 0.32 1.53 ± 0.16 2.30 ± 0.00 3.35 ± 0.28 1.15 ± 0.00 1.52 ± 0.16 0.50
SOD2 216841_s_at NM_000636 -1.15 ± 0.00 0.66 ± 0.02 -3.14 ± 0.15 0.38 ± 0.06 1.15 ± 0.00 1.28 ± 0.07 -1.33 ± 0.26 0.51 ± 0.05 -1.15 ± 0.11 0.87 ± 0.08 -1.81 ± 0.69 0.11 ± 0.02 0.83
CYR61 201289_at NM_001554 -2.83 ± 0.00 0.23 ± 0.01 -1.11 ± 0.05 1.00 ± 0.05 -1.62 ± 0.00 0.53 ± 0.02 -2.30 ± 0.00 0.27 ± 0.02 -1.80 ± 0.09 0.62 ± 0.05 -0.22 ± 1.83 0.97 ± 0.15 0.92
SERPINB2 204614_at NM_002575 9.52 ± 0.47 10.18 ± 1.55 -3.14 ± 0.15 0.25 ± 0.01 1.46 ± 0.07 1.75 ± 0.14 3.49 ± 0.34 2.20 ± 0.28 -4.00 ± 0.00 0.25 ± 0.01 4.46 ± 0.65 0.58 ± 0.03 0.81
MCM5 216237_s_at NM_006739 -1.87 ± 0.18 0.33 ± 0.02 1.69 ± 0.25 1.84 ± 0.52 -1.52 ± 0.15 0.49 ± 0.02 -3.26 ± 0.32 0.23 ± 0.02 -0.07 ± 1.52 1.34 ± 0.32 -2.35 ± 0.68 1.08 ± 0.22 0.37
GADD45B 207574_s_at NM_015675 -1.87 ± 0.18 0.30 ± 0.03 -1.23 ± 0.12 0.69 ± 0.07 -0.28 ± 1.91 0.79 ± 0.09 -3.38 ± 0.50 0.16 ± 0.03 -1.57 ± 0.08 0.83 ± 0.15 -1.37 ± 0.20 0.27 ± 0.02 0.71
GC RT-PCR GC RT-PCRGC RT-PCR GC RT-PCRGC RT-PCR GC RT-PCR
Pre CHL + co-treatment  vs vehicle control ( avg. FC ± SD)
 1 (M98035)  2 (M99005) 3 (M98015) 4 (M98025)  5 (M99025)  6 (M99016)
 
A negative sign for FC by gene-chip (GC) refers to down-regulation of gene- expression by the corresponding value. 
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Table 10: Correlation of FC on gene-chip (GC) versus RT-PCR for a selected set of 
immune response genes altered by SLR ≥ 1.5 in at least one of the 6 NHMECs on 
treatment with BP in the absence or presence of CHL 
 
 
Correlation (r) Correlation (r)
FC by GC vs RT FC by GC vs RT
M98035 2.00 ± 0.20 3.68 ± 0.56 3.03 ± 0.00 3.47 ± 3.03
M99005 1.23 ± 0.00 1.68 ± 0.05 -1.46 ± 0.07 0.62 ± -1.46
M98015 2.83 ± 0.00 5.21 ± 0.73 3.73 ± 0.00 5.61 ± 3.73
M98025 2.02 ± 0.39 1.29 ± 0.05 2.55 ± 0.12 1.22 ± 2.55
M99025 1.94 ± 0.28 3.20 ± 0.51 1.32 ± 0.00 1.41 ± 1.32
M99016 5.89 ± 0.86 11.52 ± 1.20 5.89 ± 0.86 7.44 ± 5.89
M98035 3.06 ± 0.60 2.87 ± 0.34 1.87 ± 0.00 0.65 ± 0.09
M99005 2.17 ± 0.93 5.17 ± 1.15 1.64 ± 0.32 1.83 ± 0.29
M98015 2.65 ± 0.26 9.22 ± 1.19 1.88 ± 0.37 4.17 ± 0.53
M98025 2.38 ± 0.12 4.87 ± 0.96 0.05 ± 1.93 2.07 ± 0.70
M99025 1.52 ± 0.15 4.84 ± 0.77 1.23 ± 0.00 1.67 ± 0.18
M99016 3.41 ± 0.83 8.76 ± 0.56 3.49 ± 0.34 3.60 ± 0.50
M98035 1.32 ± 0.00 1.60 ± 0.13 1.87 ± 0.00 1.33 ± 0.05
M99005 1.04 ± 0.05 1.59 ± 0.16 -0.53 ± 1.55 0.53 ± 0.01
M98015 1.28 ± 0.06 1.77 ± 0.15 1.52 ± 0.15 1.47 ± 0.06
M98025 1.52 ± 0.00 0.93 ± 0.06 3.26 ± 0.32 1.39 ± 0.08
M99025 -1.15 ± 0.00 1.39 ± 0.16 -1.19 ± 0.06 1.01 ± 0.10
M99016 -0.17 ± 1.76 1.23 ± 0.44 2.25 ± 0.55 1.76 ± 0.36
M98035 1.41 ± 0.00 1.66 ± 0.11 2.25 ± 0.55 1.64 ± 0.17
M99005 1.19 ± 0.06 1.91 ± 0.11 -1.37 ± 0.07 0.73 ± 0.03
M98015 1.21 ± 0.29 1.57 ± 0.17 1.68 ± 0.08 2.28 ± 0.21
M98025 1.41 ± 0.00 1.17 ± 0.25 3.04 ± 0.30 1.62 ± 0.09
M99025 0.09 ± 1.75 1.94 ± 0.16 1.15 ± 0.11 1.13 ± 0.14
M99016 -0.12 ± 1.69 0.78 ± 0.25 1.83 ± 0.44 2.40 ± 1.05
M98035 2.82 ± 0.60 1.43 ± 0.28 7.51 ± 0.87 5.63 ± 1.89
M99005 1.54 ± 0.07 1.19 ± 0.06 0.48 ± 0.10 -2.08 ± 0.30
M98015 1.29 ± 0.09 1.11 ± 0.05 1.40 ± 0.10 1.37 ± 0.07
M98025 1.03 ± 0.08 1.42 ± 0.14 3.05 ± 0.17 5.47 ± 0.27
M99025 1.58 ± 0.97 0.05 ± 2.07 0.36 ± 0.13 -2.87 ± 1.22
M99016 2.95 ± 0.38 1.69 ± 0.25 5.44 ± 1.15 5.74 ± 3.19
M98035 -1.93 ± 0.09 0.70 ± 0.09 -2.08 ± 0.30 0.26 ± 0.04
M99005 -1.19 ± 0.06 1.62 ± 0.16 -2.38 ± 0.12 0.53 ± 0.06
M98015 1.46 ± 0.07 2.31 ± 0.19 1.04 ± 0.05 1.23 ± 0.12
M98025 0.00 ± 2.00 1.05 ± 0.55 -3.04 ± 0.30 0.17 ± 0.02
M99025 1.19 ± 0.06 1.97 ± 0.48 -1.37 ± 0.20 0.75 ± 0.04
M99016 1.21 ± 0.29 1.67 ± 0.29 1.23 ± 0.12 0.63 ± 0.02
M98035 1.32 ± 0.13 1.34 ± 0.08 1.57 ± 0.60 0.55 ± 0.12
M99005 1.19 ± 0.06 1.85 ± 0.37 -2.14 ± 0.00 0.19 ± 0.02
M98015 1.07 ± 0.11 0.96 ± 0.10 -4.46 ± 0.65 0.10 ± 0.04
M98025 1.99 ± 0.67 1.14 ± 0.10 1.28 ± 0.19 0.16 ± 0.04
M99025 0.12 ± 1.69 2.02 ± 0.46 -1.33 ± 0.12 0.51 ± 0.36
M99016 -1.80 ± 0.09 0.93 ± 0.32 -2.39 ± 0.91 0.20 ± 0.04
Treatment
BP versus control vehicle FC
IL1B
GC RT-PCR GC RT-PCR
Pre CHL + co versus control vehicle FC
0.97 0.88
CXCL2
MX1
Gene Cell strain
IL1RN
SECTM1
CD86
PI3
0.33 0.43
0.760.12
0.530.16
0.640.28
0.770.79
0.41 0.86
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4.2.2 CYP1A1 and CYP1B1 expression in 20 NHMECs on treatment with BP in the 
absence or presence of CHL 
Wide inter-individual variations were observed both in the induction and modulation of 
CYP1A1 (Table 11) and CYP1B1 (Table 12) following treatment of 20 NHMECs with BP in the 
absence or presence of CHL. The basal expression of CYP1A1 was highest in M98014 (∆Ct = 
11.18) and lowest in M99005 (∆Ct =16.61). The basal expression of CYP1B1 was highest in 
M99016 (∆Ct = 4.19) and lowest in M98015 (∆Ct = 9.77). Overall, the average basal expression 
of CYP1A in the 20 NHMECs (∆Ct = 13.44) was 53 fold lower than that of CYP1B1 (∆Ct = 
7.72). The basal expression in terms of ∆Ct for the 20 NHMECs is presented in Table 13.  
All CHL treatments caused mitigation of CYP1A1 and CYP1B1 expression in 18/20 cell 
strains (4-88% reduction across the different CHL treatments) and 17/20 cell (4-83% reduction 
across the different CHL treatments) strains respectively, compared to those treated with BP 
alone.  
CHL co-treatment mitigated CYP1A1 and CYP1B1 expression in all 20 cell strains. 
CYP1A1 expression in the presence of CHL co-treatment ranged from 2-62 fold (4-75% 
reduction compared to cells treated with BP alone) while that of CYP1B1 ranged from 1-36 fold 
(4-67% reduction). 
Pre CHL + post BP treatment enhanced BP induced CYP1A1 expression in 2/20 cell 
strains (3% and 81% in M98011 and M98014, respectively) while decreasing it in the remaining 
18/20 cell strains (11-76% reduction). CYP1B1 expression was also enhanced by pre CHL + post 
BP treatment in 3/20 cell strains (30%, 20% and 11% in M98019, M98011 and M99006, 
respectively) while decreasing it in the remaining 17/20 cell strains (8-60% reduction).  
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Table 11: Inter-individual variations in the induction and modulation of CYP1A1 upon 
exposure of NHMECs to either BP alone or in combination with CHL  
 
1 2 3 4
Cell strain
M98019 3.62 ± 1.04 1.85* ± 0.53 3.03 ± 0.63 2.38 ± 0.83
M98014 4.57 ± 1.52 2.79 ± 0.25 8.25 ± 1.91 5.90 ± 0.91
M98011 5.36 ± 1.98 5.12 ± 0.99 5.50 ± 0.56 4.99 ± 2.63
M99021 5.90 ± 1.46 3.73 ± 1.61 3.75* ± 0.36 3.59* ± 0.52
M99006 6.46 ± 1.54 4.21 ± 1.01 5.31 ± 0.61 3.49 ± 0.80
M99025 6.58 ± 2.94 4.06 ± 1.59 2.62 ± 0.48 1.65* ± 0.46
M00004 7.07 ± 2.53 4.02 ± 0.48 4.35 ± 0.81 3.79 ± 1.41
M98025 11.22 ± 3.22 6.01* ± 2.61 9.76 ± 1.62 6.94 ± 0.65
M98035 13.83 ± 2.89 12.82 ± 2.01 9.70 ± 1.93 5.29* ± 1.58
M99005 13.69 ± 1.35 7.89* ± 1.69 8.14* ± 1.11 4.11* ± 1.37
M99003 14.27 ± 5.02 10.21 ± 2.29 11.49 ± 1.60 13.02 ± 3.96
M00012 17.09 ± 2.89 11.00 * ± 1.72 12.19* ± 2.80 9.82* ± 2.68
M99004 20.25 ± 2.06 10.78* ± 3.96 10.54* ± 3.42 11.55* ± 1.58
M98016 32.50 ± 3.40 9.99* ± 2.25 13.2* ± 1.35 6.09* ± 2.02
M99015 35.88 ± 4.71 20.75* ± 3.02 31.78 ± 2.69 29.91 ± 9.71
M98030 44.32 ± 12.41 18.54* ± 1.53 25.50* ± 2.09 15.97* ± 4.05
M98015 49.95 ± 6.64 44.79 ± 12.10 42.59 ± 10.52 47.42 ± 9.35
M98026 52.71 ± 12.93 38.99 ± 10.16 31.34* ± 11.54 30.27* ± 5.99
M98013 66.72 ± 12.10 16.36* ± 6.40 14.72* ± 6.90 8.03* ± 4.95
M99016 95.84 ± 9.86 62.36* ± 20.75 62.36* ± 4.82 53.54* ± 5.38
CYP1A1
Treatment
 
 
Treatments - 1-BP alone, 2-co-treatment, 3-Pre CHL+ post BP treatment, 4-Pre CHL + co-treatment (Details 
of treatments in Materials and methods) 
Numbers shown represent fold change ± standard deviation (n = 2) as measured by RT-PCR 
* = statistically significant reduction in expression (p ≤ 0.05) compared to expression induced by BP alone 
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Table 12: Inter-individual variations in the induction and modulation of CYP1B1 upon 
exposure of NHMECs to either BP alone or in combination with CHL  
 
1 2 3 4
Cell strain
M98019 6.09 ± 0.38 4.40 ± 1.95 7.90 ± 1.00 6.77 ± 1.79
M98014 3.49  ± 0.58 2.92 ± 0.90 1.93* ± 0.18 1.86* ± 0.25
M98011 4.74 ± 0.86 3.69 ± 0.63 5.69 ± 0.90 6.32 ± 1.53
M99021 8.75 ± 1.41 5.78* ± 1.01 6.27* ± 1.20 5.46* ± 0.86
M99006 8.92 ± 1.57 5.54* ± 0.44 9.88 ± 3.36 4.80* ± 0.76
M99025 22.86 ± 3.92 11.35 ± 3.09 9.19 ± 1.15 6.50 ± 1.26
M00004 7.92 ± 2.62 5.10 ± 0.54 7.31 ± 2.91 4.53 ± 1.95
M98025 8.41 ± 2.23 4.42* ± 1.81 4.81* ± 1.50 3.88* ± 0.54
M98035 9.46 ± 1.89 7.97 ± 1.84 7.31 ± 1.75 3.32 ± 0.40
M99005 9.16 ± 1.78 7.48 ± 0.42 5.82* ± 1.65 3.49* ± 1.30
M99003 19.66 ± 1.86 13.02* ± 1.22 15.27* ± 0.97 16.48 ± 5.15
M00012 17.54 ± 3.14 10.32* ± 1.65 14.67 ± 4.43 11.90* ± 3.29
M99004 12.13 ± 1.25 7.67* ± 1.34 6.96* ± 0.72 6.89* ± 0.83
M98016 14.65 ± 2.98 6.16* ± 0.61 10.04 ± 5.87 3.86* ± 1.12
M99015 33.88 ± 1.73 13.50* ± 2.25 22.59 ± 11.19 19.94* ± 3.73
M98030 16.00 ± 4.12 7.01* ± 1.35 6.45* ± 0.99 4.89* ± 1.77
M98015 43.41 ± 4.80 35.88* ± 3.30 39.74* ± 9.32 39.26 ± 6.89
M98026 31.67 ± 3.34 21.08* ± 1.69 24.21 ± 8.40 23.55 ± 6.40 
M98013 42.01 ± 6.89 13.95* ± 1.46 11.49* ± 1.88 7.00* ± 3.24
M99016 8.94 ± 1.39 8.60 ± 1.61 8.27 ± 1.08 6.92 ± 1.26
CYP1B1
Treatment
 
 
Treatments - 1-BP alone, 2-co-treatment, 3-Pre CHL+ post BP treatment, 4-Pre CHL + co-treatment (Details 
of treatments in Materials and methods) 
Numbers shown represent fold change ± standard deviation (n = 2) as measured by RT-PCR 
* = statistically significant reduction in expression (p ≤ 0.05) compared to expression induced by BP alone 
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Table 13: Basal CYP1A1 and CYP1B1 expression levels (∆Ct) in the 20 NHMECs 
normalized to that of GAPDH 
 
Cell strain CYP1A1 CYP1B1
M98019 15.39 8.67
M98014 11.18 6.75
M98011 12.92 7.80
M99021 11.30 7.62
M99006 12.26 8.32
M99025 15.05 8.63
M00004 12.26 7.03
M98025 12.10 6.35
M98035 15.05 7.48
M99005 16.61 6.06
M99003 13.48 8.70
M00012 12.78 7.92
M99004 12.46 7.65
M98016 13.43 7.60
M99015 12.34 9.29
M98030 15.60 6.62
M98015 12.18 9.77
M98026 12.99 8.81
M98013 13.93 8.84
M99016 15.86 4.19
Basal expression levels (∆Ct)
 
Average  13.46             7.71 
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Pre CHL + post co-treatment enhanced CYP1A1 expression in 1/20 cell strains (29% in 
M98014) while decreasing it in the remaining 19/20 cell strains (5-88% reduction). CYP1B1 
expression was enhanced in 2/20 cell strains (11% and 33% in M98019 and M98011 respectively) 
while decreasing it in the remaining 18/20 cell strains (10-83% reduction). 
There was a poor correlation between CYP1A1 and CYP1B1 induction on treatment with 
BP alone (r2 = 0.28) and by pre CHL + post BP treatment (r2 = 0.29) but a moderate correlation on 
co-treatment (r2 = 0.41) and pre CHL + post co-treatment (r2 = 0.47) (Figure 13). The correlation 
between the percentage modulation in the expression of CYP1A1 to that of CYP1B1 on co-
treatment as well as pre CHL + post co-treatment was moderate (r2 = 0.46, 0.41, respectively) and 
absent on treatment with pre CHL + post BP (r2 = 0.09) (Figure 14).  
This was mainly due to the presence of several outliers in pre CHL + post BP treatment 
(M98011 and M98014 for CYP1A1 and M98019, M98011 and M99006 for CYP1B1) and pre 
CHL + post co-treatment groups (M98014 for CYP1A1 and M98019 and M98011 for CYP1B1). 
Removal of these outliers from the analysis significantly improved the correlation between the 
percentage modulation in the expression of CYP1A1 to that of CYP1B1 upon pre CHL + post co-
treatment (r2 = 0.73). However, the correlation between the modulation of CYP1A1 to that of 
CYP1B1 on pre CHL + post BP treatment improved only marginally (r2 = 0.34).  
The correlation (r2) between CYP1A1 expression by BP alone and in the presence of 
different CHL treatments was 0.78, 0.78 and 0.64 for co-treatment, pre CHL + post BP treatment 
and pre CHL + post co-treatment, respectively (Figure 15). The correlation (r2)  
between CYP1B1 expression by BP alone and in the presence of different CHL treatments 
was 0.72, 0.66 and 0.57 for co-treatment, pre CHL + post BP and pre CHL + post co-
treatment, respectively) (Figure 16). 
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Figure 13: Correlation of CYP1A1 expression to that of CYP1B1 in the 20NHMECs 
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Figure 14: Correlation between the percentage modulation in the expression of 
CYP1A1 to that of CYP1B1 
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Figure 15: Correlation of CYP1A1 expression in the absence and presence 
of CHL 
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Figure 16: Correlation of CYP1B1 expression in the absence and presence of CHL 
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4.2.3 CYP1A1 and CYP1B1 expression in 2 NHMECs on treatment with BP or B[e]P in 
the absence or presence of CHL 
With respect to studies on comparison of BP versus B[e]P in the induction of 
CYP1A1 and CYP1B1 wide ‘inter’ cell strain differences were observed in the induction and 
modulation of both CYP1A1 and CYP1B1 in both M98015 and M98025 on treatment with 
BP or B[e]P in the absence or presence of CHL (Figures 17 and 18). 
The induction of both CYP1A1 and CYP1B1 by BP was comparatively higher in 
M98015 than M98025 (35 fold versus 10 fold for CYP1A1 and 23 fold versus 5 fold for 
CYP1B1). Though B[e]P was a very poor inducer of both CYP1A1 and CYP1B1 in M98015 
(2 fold and 1 fold, respectively) and M98025 (0.7 fold and 1 fold, respectively) compared to 
BP, the induction of CYP1A1 by B[e]P was slightly higher in M98015 compared to M98025 
(2 fold versus 0.7 fold). The induction CYP1B1 by B[e]P, however, showed little difference 
between M98015 and M98025.  
CHL co-treatment caused a statistically significant decrease of BP induced CYP1A1 
expression in M98015 and M98025 (30% and 37% respectively, p< 0.05 for both). CHL co-
treatment also caused a decrease of BP induced CYP1B1 expression in both M98015 and 
M98025 (42% and 21%, respectively) with the reduction in M98015 being statistically 
significant (p< 0.05). In the case of B[e]P, all CHL co-treatments caused an increase in the 
expression of B[e]P induced CYP1A1 and CYP1B1 in both M98015 (148%, p<0.005 and 
219%, p = 0.005,  respectively) and M98025 (75%, p<0.005 and 132%, p<0.05 respectively). 
Pre CHL + post BP treatment did not mitigate BP induced expression of CYP1A1 in 
M98015 (0.17% increase) but did mitigated it in M98025 (29%). The expression of BP 
induced CYP1B1 was reduced only slightly in M98015 (5%) but significantly in M98025 
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(50%, p<0.05). Pre CHL + post BP treatment caused a mitigation of B[e]P induced CYP1A1 
and CYP1B1 expression in M98015 (3% and 4%, respectively) and M98025 (19% and 54%, 
respectively). 
Pre CHL + co-treatment did not modulate the expression of BP induced CYP1A1 in 
M98015 but caused a statistically significant decrease in the expression of CYP1A1 in 
M98025 (40%, p<0.05). The expression of CYP1B1 was significantly reduced in both 
M98015 and M98025 (35% and 47% respectively, p<0.05 for both). There was a statistically 
significant increase in the expression of B[e]P induced CYP1A1 in M98015 (155%, p<0.005) 
and M98025 (112%, p<0.05) upon pre CHL + co-treatment. The expression of B[e]P induced 
CYP1B1 was increased in M98015 (62%, p<0.05) but decreased in M98025 (25%). 
The correlation (r2) of BP induced CYP1A1 expression to that of CYP1B1 expression 
across all treatments for M98015 and M98025 was 0.47 and 0.54, respectively. The 
correlation (r2) of B[e]P induced CYP1A1 expression to that of CYP1B1 expression across all 
treatments for M98015 and M98025 was 0.97 and 0.71, respectively. 
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Figure 17: Comparison of CYP1A1 expression by BP or B[e]P in (A) M98015 and (B) 
M98025 in the absence or presence of CHL.  
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre CHL 
+ post co-treatment.  
* indicates a statistically significant reduction in CYP1A1 expression compared to BP alone 
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Figure 18: Comparison of CYP1B1 expression by BP or B[e]P in (A) M98015 and (B) 
M98025 in the absence or presence of CHL.  
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre CHL 
+ post co-treatment.  
* indicates a statistically significant reduction in CYP1B1 expression compared to BP alone 
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4.2.4 CYP1A1 and CYP1B1 expression in MCF-7 and M00012 on treatment with BP in 
the absence or presence of CHL 
Comparison of MCF-7 with a NHMEC (M00012) across various CHL treatments (as 
detailed in Table 3 of Materials and Methods) revealed that though basal CYP1A1 expression 
was comparable for both MCF-7 and M00012 (∆Ct = 12.8 for both), CYP1B1 expression was 
much higher in MCF-7 (∆Ct = 4.37) as compared to M00012 (∆Ct = 7.92). The basal 
expression level of CYP1B1 in MCF-7 cells was 348 times that of CYP1A1 whereas that of 
M00012 was only 29 times that of CYP1A1. The basal expression of CYP1B1 in MCF-7 was 
nearly 12 times that in M00012. The induction of CYP1A1 by BP alone was 114 fold 
whereas that of CYP1B1 was only 5 fold in MCF-7. All CHL treatments caused an increase 
of BP induced CYP1A1 (16%, 22% and 23% increase on co-treatment, pre CHL + post BP 
treatment and pre CHL + post co-treatment, respectively) and CYP1B1 (11%, 12% and 33% 
increase on co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment 
respectively) expression. In the case of M00012, all CHL treatments caused a mitigation of 
BP induced CYP1A1 (36%, 29% and 43% decrease on co-treatment, pre CHL + post BP 
treatment and pre CHL + post co-treatment, respectively) and CYP1B1 (41%, 16% and 32% 
decrease on co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment, 
respectively).  
The overall correlation of CYP1A1 expression to that of CYP1B1 expression across 
all treatments was moderate for MCF-7 and good for M00012 (r2 = 0.61 and 0.80 for MCF-7 
and M00012, respectively).  
A comparison of the extent of CYP1 expression between MCF-7 and 20 NHMECs 
used in the above studies was also carried out in order to have a comparison against response 
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patterns of a broad panel of cell strains. Such a comparison against a broad panel would take 
into account inter-cell strains differences in induction and modulation. The basal CYP1A1 
and CYP1B1 expression in MCF-7 was higher than the average basal CYP1A1 and CYP1B1 
expression across all the 20 NHMECs (∆Ct = 12.81 and 4.37 for CYP1A1 and CYP1B1 in 
MCF-7 versus 13.46 and 7.71 for CYP1A1 and CYP1B1 in the 20 NHMECs). This 
corresponds to a 2 fold higher expression of CYP1A1 and a10 fold higher expression level of 
CYP1B1 in MCF-7 versus the 20 NHMECs. The average basal CYP1B1 expression in the 20 
NHMECs was 53 fold that of CYP1A1. The expression patterns of CYP1A1 and CYP1B1 on 
treatment of the 20 NHMECs with BP alone or in the presence of different CHL treatments 
are presented in Tables 11 and 12, respectively. The induction of CYP1A1 by BP alone in 
MCF-7 (114 fold) was much higher than even the highest inducer in the 20 NHMECs (96 
fold in M99016). This held true for even the other CHL treatments (co-treatment, pre CHL + 
post BP treatment and pre CHL + post co-treatment). With regard to CYP1B1 expression, the 
expression in MCF-7 by BP in the absence and presence of CHL was in the range of the 20 
NHMECs. Figures 19 and 20 depict the expression patterns of CYP1A1 and CYP1B1, 
respectively in MCF-7 and M00012 across the different treatment groups. In each case the 
inset shows the expression pattern of MCF-7 in comparison with the other 20 NHMECs. 
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Figure 19:  (A) CYP1A1 expression patterns on treatment of MCF-7 cells or M00012 (a 
NHMEC) with BP in the absence or presence of CHL. (B) CYP1A1 expression patterns in 
MCF-7 versus 20 NHMECs. The expression of CYP1A1 in MCF-7 cells is much higher and 
different compared to the NHMECs. 
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre CHL 
+ post co-treatment.  
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Figure 20: (A) CYP1B1 expression patterns on treatment of MCF-7 cells or M00012 (a 
NHMEC) with BP in the absence or presence of CHL. (B) CYP1B1 expression patterns in 
MCF-7 versus 20 NHMECs. The expression of CYP1B1 in MCF-7 cells was in the range of 
the NHMECs. 
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre CHL 
+ post co-treatment. 
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4.2.5 CYP1A1 and CYP1B1 expression in MCF-7 and M00012 on treatment with BP in 
the absence or presence of different CHL concentrations 
With regard to the effect of a range of CHL concentrations on BP induced CYP1A1 
and CYP1B1 expression in MCF-7 cells, BP induced CYP1A1 expression 38 fold while that 
of CYP1B1 was induced only 3 fold. Pre CHL + post co-treatment enhanced BP induced 
CYP1A1 expression of cells at low concentrations of CHL (2 μM, 3 μM and 4 μM) in MCF-7 
cells. The induction of CYP1A1 was 100 fold, 260 fold and 48 fold on pre-treatment with 
CHL 2μM, 3 μM or 4 μM, respectively followed by co-treatment. However, higher 
concentrations of CHL (8 μM and 16 μM) mitigated BP induced CYP1A1 expression on pre-
treatment with CHL followed by the respective post co-treatment, though there did not 
appear to be a concentration dependent response. The fold induction of CYP1A1 on pre 8 μM 
CHL + post co-treatment and pre 16 μM CHL + post co-treatment was 24 fold and 36 fold, 
respectively. The expression of CYP1B1 however was not altered across the different CHL 
concentrations in MCF-7. All CHL concentrations caused a slight increase of BP induced 
CYP1B1 expression. CYP1B1 expression on treatment of MCF-7 cells with BP alone and in 
the presence of 2 μM, 3 μM, 4 μM, 8 μM and 16 μM CHL in a pre CHL + post co-treatment 
were 3, 3, 4, 4, 4 and 3 fold, respectively.  
In the case of M00012, highest CYP1A1 expression was in the group treated with BP 
alone (23 fold) while all CHL treatments except pre 8 μM + post co-treatment mitigated BP 
induced CYP1A1 expression to different extents (21, 13, 19, 23 and 2 fold on pre-treatment 
with 2 μM, 3 μM, 4 μM, 8 μM and 16 μM CHL followed by co-treatment, respectively). 
With respect to CYP1B1 expression, again there did not appear to be a concentration 
dependent response. The induction of CYP1B1 by BP was 8 fold whereas the induction in the 
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presence of 2 μM, 3 μM, 4 μM, 8 μM and 16 μM CHL pre-treatment followed by co-
treatment was 10, 5, 3, 16 and 3 fold, respectively. The correlation (r2) of CYP1A1 
expression to CYP1B1 expression by BP in the absence or presence of a range of CHL 
concentrations in MCF-7 cells was 0.24 while that in M00012 was 0.41. The expression 
patterns of CYP1A1 or CYP1B1 in MCF-7 and M00012 by BP in the absence or presence of 
a range of CHL concentrations are shown in Figures 21 and 22, respectively. 
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Figure 21: CYP1A1 expression patterns in MCF-7 and M00012 by BP in the 
absence or presence of a range of CHL concentrations. 
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Figure 22: CYP1B1 expression patterns in MCF-7 and M00012 by BP in the 
absence or presence of a range of CHL concentrations. 
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4.3 DNA adducts 
4.3.1 BP-DNA adducts in 20 NHMECs on treatment with BP in the absence or presence 
of CHL 
The levels of BP-DNA adducts across the 20 NHMECs exhibited considerable inter-
individual variation with highest levels being in the BP treated group (Table 14). All CHL 
treatments lowered BP-DNA adducts in most cell strains except in M99021 (which exhibited an 
increase in adduct levels upon co-treatment and pre CHL + post BP treatment) and M99025 (which 
showed no reduction in adduct levels upon CHL co-treatment). The number of BP-DNA adducts in 
the BP treated group ranged from 2.5 adducts/108 nucleotides (in M99005) to 57.5 adducts/108 
nucleotides (M99015).  
CHL co-treatment caused a decrease in BP-DNA adduct levels in 18/20 cell strains (13-
55% reduction) while increasing it in M99021 (5% increase) and having no effect in M99025. The 
average reduction in BP-DNA adducts by CHL co-treatment was 33%. Pre CHL + post BP 
treatment caused a reduction in BP- DNA adduct levels in 19/20 cell strains (3-67%) while 
increasing it in M99021 (12% increase). The average reduction in BP-DNA adducts by CHL pre-
treatment followed by post BP treatment was 28%. Pre CHL + post co-treatment caused a 
reduction in BP-DNA adducts in all cell strains (28-87%). The average reduction in BP-DNA 
adducts by CHL pre-treatment followed by post co- treatment was 53%. As evident, the maximum 
reduction in BP-DNA adducts for most cell strains was by pre CHL + post co-treatment except in 
M99015, M98019 and M99005.  
There was a good correlation between the levels of BP-DNA adducts in the presence of BP 
alone and by CHL co-treatment (r2 =0.90) as well as pre CHL + post BP treatment (r2= 0.89). 
However, their correlation in the presence of pre CHL + post co-was only moderate (r2= 0.68). 
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Table14: Inter-individual variations in BP-DNA adduct formation on exposure of NHMECs 
to either BP alone or in combination with CHL  
 
 
Cell strain 1 2 3 4
M99005 2.45 ± 1.34 1.25 ± 1.20 2.20 ± 2.26 1.50 ± 1.70
M99025 3.15 ± 0.64 3.15 ± 0.21 2.50 ± 1.27 1.35 ± 0.07
M98014 4.67 ± 0.61 2.24* ± 0.35 2.87* ± 0.15 2.10* ± 0.73
M99004 4.75 ± 0.49 2.75 ± 0.64 2.30 ± 0.99 1.90 ± 0.85
M98019 5.09 ± 0.94 3.05* ± 1.29 3.22* ± 0.81 3.59 ± 1.11
M98035 5.85 ± 3.89 2.70 ± 1.13 5.70 ± 1.56 2.65 ± 1.34
M99003 7.25 ± 1.48 3.30 ± 0.28 3.45 ± 1.20 1.30 ± 0.42
M98015 8.30 ± 4.95 5.50 ± 3.25 5.45 ± 4.03 4.30 ± 4.10
M98030 9.47 ± 1.52 8.12 ± 3.26 5.53 ± 1.78 4.00 ± 1.63
M99021 13.66 ± 3.16 14.29 ± 1.49 15.32 ± 3.76 10.21 ± 5.40
M98025 15.10 ± 2.40 5.10 ± 0.57 4.95 ± 1.77 3.70* ± 2.40
M99006 17.32 ± 3.70 13.59 ± 3.25 15.49 ± 5.75 12.56 ± 4.14
M98011 20.83 ± 13.03 15.33 ± 13.06 17.84 ± 9.19 11.73 ± 9.25
M00012 21.0 ± 4.53 14.65 ± 1.77 16.35 ± 3.46 10.85 ± 3.32
M98013 23.13 ± 1.96 14.45* ± 2.75 12.18* ± 1.23 3.00* ± 0.91
M00004 33.41 ± 6.12 27.05 ± 13.72 28.33 ± 9.63 19.83 ± 12.34
M99016 34.00 ± 3.39 23.85 ± 3.61 25.45 ± 2.62 12.50* ± 1.41
M98016 53.38 ± 2.52 26.05* ± 2.32 25.59* ± 7.00 7.04* ± 1.37
M98026 54.46 ± 29.74 47.29 ± 26.00 42.49 ± 21.40 32.49 ± 18.19
M99015 57.49 ± 16.23 34.99 ± 15.88 51.40 ± 12.08 35.43 ± 10.79
BP-DNA adducts/108 nt.
Treatment
` 
 
Treatments - 1-BP alone, 2-co-treatment, 3-Pre CHL+ post BP treatment, 4-Pre CHL + co-treatment (Details of 
treatments in Materials and methods) 
Numbers shown represent fold change ± standard deviation (n = 2) as measured by CIA 
* = statistically significant reduction in expression (p ≤ 0.05) compared to expression induced by BP alone 
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4.3.2 BP-DNA and B[e]P-DNA adducts in 2 NHMECs on treatment with BP or B[e]P in 
the absence or presence of CHL 
In the comparison between M98015 and M98025 on treatment with BP or B[e]P in 
the absence or presence of CHL, both cell strains had the highest number of BP-DNA 
adducts in cells treated with BP alone (8.3 and 15.1 adducts/108 nucleotides in M98015 and 
M98025, respectively). All CHL treatments reduced the levels of BP-DNA adducts in 
M98015 (34%, 34% and 48% reduction for co-treatment, pre CHL + post BP and pre CHL + 
post co-treatment, respectively) and M98025 (66%, 67% and 76% for co-treatment, pre CHL 
+ post BP and pre CHL + post co-treatment, respectively). B[e]P-DNA adducts were not 
detectable by synchronous fluorescence spectrometry in B[e]P as well as the CHL treatment 
groups (B[e]P co-treatment, pre CHL + post B[e]P treatment and pre CHL + post  B[e]P co-
treatment ) in both M98015 and M98025. Benzo(a)pyrene-r-7,t-8,c-9,t-10-tetrahydrotetrol 
was used as a standard to construct the standard curve and the synchronous spectra of one of 
the dilutions is shown in Figure 23. Similarly, the synchronous spectra of the B[e]P treated 
cells in M98015 and M98025 are shown in Figure 24.  
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Figure 23: Synchronous fluorescence spectra obtained from standard   
benzo(a)pyrene-r-7,t-8,c-9,t-10-tetrahydrotetrol. The spectra shown here 
was generated using 80fM of the standard 
Figure 24: Synchronous spectra of the B[e]P treated cells (A) M98015 and 
(B) M98025 
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4.3.3 BP-DNA adducts in MCF-7 and M00012 or 20 NHMECs on treatment with BP in 
the absence or presence of CHL 
Comparison of adducts formed in MCF-7 versus M00012 (NHMEC) following 
treatment with BP alone or in the presence of CHL, MCF-7 exhibited adduct levels greater  
than 25 orders of magnitude of that of M00012 for all the treatment groups (BP alone, co-
treatment, pre CHL + post BP treatment and pre CHL + post co-treatment). 609 BP-DNA 
adducts /108 nucleotides were detected in MCF-7 on treatment with BP alone as opposed to 
only 21 BP-DNA adducts /108 nucleotides in M00012. None of the CHL treatments 
mitigated BP-DNA adduct levels in MCF-7 (3% reduction on co-treatment, 17 and 6% 
increase, pre CHL + post BP treatment and pre CHL + post co-treatment, respectively). 
M00012 on the other hand exhibited a reduction of BP-DNA adduct levels in all CHL 
treatment groups (30%, 22% and 48% reduction on co-treatment, pre CHL + post BP 
treatment and pre CHL + post co-treatment, respectively).  
In comparison with 20 NHMECs, MCF-7 cells exhibited adduct levels greater than 
10 orders of magnitude than the highest number of adducts formed in the 20 NHMECs. This 
was true across all treatment groups (BP, co-treatment, pre CHL + post BP treatment and pre 
CHL + post co-treatment). The average reduction of BP-DNA adducts across different CHL 
treatments among the 20 NHMECs were 33%, 28% and 53% on co-treatment, pre CHL + 
post BP treatment and pre CHL + post co-treatment, respectively as opposed to no mitigation 
in BP-DNA adduct levels in MCF-7 across the different CHL treatments. The adduct levels 
in MCF-7 and M00012 on treatment with BP in the absence or presence of CHL are 
presented in Figure 25.  
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Figure 25: BP-DNA adduct levels/108 nucleotides in MCF-7 and M00012 on treatment 
with BP in the absence or presence of different CHL treatments. The inset on the right 
shows the BP-DNA adduct levels in MCF-7 versus that in 20 NHMECs.  
Treatments: 1= BP alone, 2 = co-treatment, 3 = Pre CHL + post BP treatment, 4 = Pre 
CHL + post co-treatment. 
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4.3.4 BP-DNA adducts in MCF-7 and M00012 on treatment with BP in the absence or 
presence of different CHL concentrations 
When compared across a range of CHL concentrations, CHL did not imitate the level 
of BP-DNA adducts across different CHL concentrations in MCF-7 cells. There was no 
concentration dependent response and even the highest concentration of CHL (16 μM) did 
not cause any reduction in the level of BP-DNA adducts. However, there was concentration 
dependent reduction in the levels of BP-DNA adducts in M00012 for all CHL concentrations 
except for pre-treatment with 2 μM CHL followed by co- treatment (8% increase compared 
to cells treated with BP alone). The reduction in BP-DNA adduct levels across all the other 
CHL treatments were 19%, 25%, 36% and 66% for pre-treatment with 3 μM, 4 μM, 8 μM 
and 16 μM CHL followed by co-treatment respectively. The reduction in adduct levels at the 
higher concentrations of CHL (8 μM and 16 μM) was significant (p<0.05). The levels of BP-
DNA adducts in MCF-7 were more than 13 fold that in M00012 for BP at the lower 
concentrations of CHL (BP, 2 μM and 3 μM CHL pre-treatment followed by co-treatment), 
more than 24 fold for both 4 μM and 8 μM CHL pre-treatment followed by co-treatment) and 
82 fold for the highest concentration of CHL (pre-treatment with CHL 16 μM followed by 
co-treatment). The response patterns of MCF-7 and M00012 across a range of CHL 
concentrations are shown in Figure 26. 
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Figure 26: BP-DNA adduct levels/108 nucleotides in MCF-7 and M00012 on treatment 
with BP in the absence or presence of a range of CHL concentrations. Inset shows a 
clearer picture of the response pattern of M00012. 
* indicates statistically significant reduction compared to cells treated with BP alone 
Treatments: 1= BP alone, 2 = Pre 2 μM CHL + post co-treatment, 3 = Pre 3 μM CHL + 
post co-treatment, 4 = Pre 4 μM CHL + post co-treatment, 5 = Pre 8 μM CHL + post co-
treatment, 6 = Pre 16 μM CHL + post co-treatment 
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4.4 Correlation of CYP1 gene expression to BP-DNA adducts 
4.4.1 Correlation of cell strain origin with CYP1 gene expression and DNA adduct 
formation 
To examine the existence of a relationship, if any, between age of the donors and 
inter-individual variability in the induction of CYP1 enzymes and DNA adduct formation, a 
correlation analysis of age versus the CYP1 expression and DNA adduct levels was carried 
out across the 20 NHMECs used in the study. There was no correlation between age of the 
donors and CYP1A1 expression (r2 = 0, 0.02, 0.02 and 0.07 for BP, co-treatment, pre CHL + 
post BP treatment and pre CHL + post co-treatment, respectively), CYP1B1 expression (r2 = 
0.04, 0.15, 0.13, and 0.22 for BP, co-treatment, pre CHL + post BP treatment and pre CHL + 
post co-treatment, respectively) and BP-DNA adduct formation (r2 = 0.10, 0.11, 0.10 and 
0.07 for BP, co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment, 
respectively).  
 
4.4.2 Correlation of CYP1 expression to DNA adducts in 20 NHMECs on treatment 
with BP in the absence or presence of CHL 
In order to understand the contribution and relevance of the Ahr mechanism to BP 
metabolism, a correlation of CYP1A1 and/or CYP1B1 expression to the level of BP-DNA 
adducts was carried out. Also, the correlation (r2) of CYP1A1 expression in the presence of 
BP alone, co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment to the 
levels of BP-DNA adducts by the corresponding treatments was 0.19, 0.16, 0.16 and 0.13, 
respectively. Similarly, the correlation (r2) of CYP1B1 expression in the presence of BP 
alone, co-treatment, pre CHL + post BP treatment and pre CHL + post co-treatment to the 
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levels of BP-DNA adducts by the corresponding treatments were 0.09, 0.03, 0.11 and 0.12, 
respectively. Also, since both CYP1A1 and CYP1B1 are involved in the metabolism of BP, a 
correlation analysis of  the extent of CYP1A1 + CYP1B1 expression by BP alone, co-
treatment, pre CHL + post BP treatment and pre CHL + post co-treatment to the levels of  
BP-DNA adducts by the corresponding treatments was also carried out. The correlation (r2) 
CYP1A1 + CYP1B1 expression on treatment with BP alone, co-treatment, pre CHL + post BP 
treatment and pre CHL + post co-treatment to the levels of BP-DNA adducts by the 
corresponding treatments were 0.17, 0.13, 0.18 and 0.15, respectively. The basal expression 
of CYP1B1 was higher than that of CYP1A1.  
 
4.4.3 Correlation of CYP1 expression to DNA adducts in 2 NHMECs on treatment with 
BP or B[e]P in the absence or presence of CHL 
In a comparative study between BP and B[e]P across 2 NHMECs (M98015 and 
M98025), there was no correlation between BP induced CYP1A1 expression and the level of 
BP-DNA adducts in the absence and presence of CHL in M98015 (r2 = 0.02). However, there 
was a very good correlation in M98025 (r2 = 0.94). BP induced CYP1B1 expression in the 
absence and presence of CHL correlated moderately with the level of BP-DNA adducts in 
M98015 (r2 = 0.47) and well in M98025 (r2 = 0.74). Correlation of BP induced CYP1A1 + 
CYP1B1 expression with the level of BP-DNA adducts was poor (r2 = 0.20). 
Although B[e]P induced a low level of CYP1 expression, as mentioned in section 
4.3.2 it did not form a detectable level of DNA adducts. 
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4.4.4 Correlation of CYP1 gene expression to DNA adducts in MCF-7 and M00012 or 20 
NHMECs on treatment with BP in the absence or presence of CHL 
Comparison of CYP1 expression with the level of BP-DNA adducts in MCF-7 versus 
M00012 across different treatments (BP, co-treatment, pre CHL + post BP treatment and pre 
CHL + post co-treatment) showed a poor correlation for CYP1A1 expression versus BP-DNA 
adducts (r2 = 0.33). There was no correlation between CYP1B1 expression versus BP-DNA 
adducts (r2 = 0.06). The expression of CYP1A1 + CYP1B1 across all treatment groups versus 
BP-DNA adducts by the corresponding treatments was 0.32 and 0.92 for MCF-7 and 
M00012, respectively. When compared against all the 20 NHMECs, the correlation (r2) of 
CYP1A1 with BP-DNA adducts and CYP1B1 with BP-DNA adducts across all treatment 
groups were 0.20 and 0.12, respectively. The expression of CYP1A1 + CYP1B1 across all 
treatment groups versus BP-DNA adducts by the corresponding treatments for all 20 
NHMECs was 0.21. 
 
4.4.5 Correlation of CYP1 gene expression to DNA adducts in MCF-7 and M00012 on 
treatment with BP in the absence or presence of different CHL concentrations 
The correlation of CYP1A1 expression versus levels of BP-DNA adducts in MCF-7 cells 
on treatment with BP in the absence or presence of different CHL concentrations was poor 
(r2 = 0.16) but moderate in M00012 (r2 = 0.54). There was no correlation between CYP1B1 
expression versus levels of BP-DNA adducts in both MCF-7 cells (r2 = 0.02) and M00012 (r2 
= 0.07). The overall correlation of CYP1A1 + CYP1B1 expression to DNA adducts was poor 
for both MCF-7 (r2 = 0.16) and M00012 (r2 = 0.37). 
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5.0 DISCUSSION 
 
 
5.1 Gene expression by microarrays 
The development of cancer is a ‘multi-hit’ process requiring perturbation of a number 
of normal cellular processes and in turn the function of a multitude of genes that orchestrate 
these processes. In this study, we observed alterations both in the extent and patterns of 
expression of many genes belonging to different functional categories, on exposure to BP in 
the absence or presence of CHL. A complete list of all the genes discussed here can be found 
in Tables A, B, C, D at (http://www.cdc.gov/niosh/ext-supp-mat/MTP/index.htm). 
 
5.1.1 Genes altered by BP treatment 
Various members of the Phase I and Phase II battery of enzymes were up-regulated 
on treatment with BP. The highly consistent increase in the expression of CYP1B1 across all 
the 6 NHMEC strains may suggest its possible role as the predominant CYP isoform 
involved in the metabolism of BP to DNA binding electrophiles in most individuals. These 
results are in agreement with previous studies from our laboratory (45). It also parallels 
another study which sought to examine ‘expression signatures’ of tobacco smoke exposure in 
a population of 85 individuals using peripheral blood leukocytes. In this study, CYP1B1 was 
found to be one of the genes which consistently and significantly correlated with plasma 
cotinine concentrations (Lampe et al. 2004). The remaining members of the Phase I cluster of 
enzymes up-regulated by BP in this study (CYP39A1, FMO, and CYP1A1) are known to be 
involved in the metabolism of steroids and various endogenous substrates in addition to 
toxicants. The aldo-keto reductase family 1, member D1 (AKR1D1), an enzyme up-regulated 
by BP has been documented to be involved in prevention of oxidative free radical damage 
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apart from its role in endogenous aldehyde metabolism (Pappa et al. 2003). Its up-regulation 
may indicate to its probable role in the scavenging of any free radicals generated by catalytic 
cycling of BP (Porter et al. 1991). The aldehyde dehydrogenases ALDH1A3 and ALDH3A1 
have been reported to be involved in aldehyde detoxification generated from alcohol 
metabolism and lipid peroxidation.   
 Given some of the hallmarks of cancer being enhanced uncontrolled cell proliferation 
and dysregulation of normal cellular controls it may not be surprising that various genes 
possessing diverse roles in transcriptional regulation, cell signaling, cellular proliferation, 
cell matrix adhesion and other critical cellular processes may be targets of attack by 
carcinogens in different individuals. This might explain the alteration in the expression 
patterns of various genes belonging to these categories. They may also represent a response 
pattern of the cell to carcinogenic stress as induced by exposure to BP. The up-regulation of 
genes like the son of sevenless (SOS) (a guanine exchange factor well known for its role in 
Ras activation), STK4 (a serine threonine kinase up-regulated in certain inflammatory breast 
cancers (Bieche et al. 2004)), EREG (a member of the epidermal growth factor family found 
to exhibit enhanced expression in various epithelial tumors (Yamamoto et al. 2004)) strongly 
point to this possibility. In fact, BP has been shown to be capable transforming and 
immortalizing cells in vitro (Gudjonsson et al. 2004).  
  BP is also an immunotoxicant and has been found to lead to T cell suppression 
(Rodriguez et al. 1999) and inhibition of B cell lymphopoiesis (Hardin et al. 1992). Among 
the battery of immune response genes altered by BP, interleukin 1 beta (IL1B), a 
proinflammatory cytokine with a proangiogenic role in vivo, was consistently up-regulated in 
all the 6 cell strains on exposure to BP. This may suggest that among the many changes 
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occurring following exposure to BP, one of them could be enhanced cell proliferation and 
angiogenesis. Also, exposure to BP has been found to affect oxidative damage and immune 
system injuries probably necessitating up-regulation of inflammatory cytokines such as IL1B 
as a defense mechanism. This is similar to a study where exposure of rats to Fe2O3 or BP or 
in combination to study their role in lung cancer resulted in enhanced production of various 
inflammatory cytokines including IL1B (Garcon et al. 2001). Of the other immune response 
genes up-regulated by BP, MAL, a T cell differentiation proteolipid has been found to 
behave as a tumor suppressor (Kazemi-Noureini et al. 2004) and also has a role in apoptosis 
(Kohler et al. 1999). Any BP induced cellular damage may be triggering its up-regulation. 
Not much is known at this time about the human T-cell leukemia virus enhancer factor 
(HTLF). SECTM1 (K12), another immune response gene, is protease inhibitor thought to 
have a role in hematopoiesis and in immunogenic processes by acting as CD7 ligand (Slentz-
Kesler et al. 1998). Though initially unknown, CD7 is now known to be involved in T and 
NK cell activation and cytokine production. K12 by interacting with CD7 is, therefore, 
thought to play a role in regulation of thymocyte signaling and cytokine release (Lam et al. 
2005).  
Various other genes up-regulated by BP share an unknown association with 
carcinogenesis. While some are well characterized genes others appear to be mostly ESTs or 
sequences coding for hypothetical proteins. BEX1 and LBH are genes having a role in 
developmental regulation being involved in neurogenesis and early limb development, 
respectively (Briegel et al. 2001; Koo et al. 2005). Recently, BEX1 has been reported to be 
overexpressed in patients with acute myeloid leukemia (Quentmeier et al. 2005). These 
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might provide cues to the manner in which BP manifests some of its developmental 
toxicities.  
Alterations in expression profiles induced by BP appear to be mainly mediated 
through up-regulation of genes rather than down-regulation given that only one cell strain 
exhibited down-regulation of genes by SLR ≥ 1.5.  
Only one gene with a potential role in immune responses (CXCL14) was down-
regulated by BP. Contradictory reports exist regarding the role of CXCL14 (BRAK) with 
some studies pointing more to a role of a tumor suppressor inhibiting tumor growth 
(Schwarze et al. 2002; Shellenberger et al. 2004) and yet others reporting a role for it in 
enhanced proliferation, migration, and invasion of myoepithelial cells and myofibroblasts 
(Allinen et al. 2004). 
 Taken together, there appears to be a dual role of BP by either enhancing (in most 
cases) the expression of genes which may aid in the various aspects of carcinogenesis or in 
parallel also modulating the expression of genes which may serve to have a protective effect 
by maintaining cellular integrity. Considerable inter-individual variations in response 
patterns are also apparent with most genes not being consistently altered in all individuals 
except CYP1B1. 
 
5.1.2 Genes altered by Pre CHL + co-treatment 
CHL has been documented to modulate various aspects of carcinogenesis and 
mutagenesis either through non-specific inhibition of CYPs (Waters et al. 1996), up-
regulation of various members of the detoxification battery (Singh et al. 1996; Fahey et al. 
2005), enhancement of apoptosis (Chiu et al. 2005), modulation of carcinogen transport 
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(Mata et al. 2004), mitigation of oxidative stress (Kumar et al. 2004) or various combinations 
of these. Alteration in the expression profiles of genes belonging to various functional 
categories as seen in this study may point to additional targets of CHL. The large number of 
genes modulated by pre CHL + co-treatment may be due a ‘synergistic interaction’ between 
BP and CHL. 
CHL modulated similar functional classes of genes as those altered by BP though 
some of the individual members within each functional class were different. Most members 
of the Phase I group of enzymes are common to BP treated cells indicating that their 
expression may predominantly be affected by carcinogenic stress (BP) or the fact that CHL 
may be a ‘bifunctional inducer’ inducing Phase I enzymes too in addition to Phase II 
enzymes or both. Again, only CYP1B1 was consistently up-regulated by SLR ≥ 1.5 (except 
M99005) in all the donors while considerable inter-individual variations existed in 
expression patterns of the other genes. Several other members of the aldehyde dehydrogenase 
and aldo-keto reductase (AKR1) families, apart from the ones altered by BP treatment were 
up-regulated by CHL compared to cells treated with BP alone further indicating a 
‘bifunctional’ role of CHL. Most of these members were also up-regulated in a consistent 
fashion though not by SLR ≥ 1.5 in all 6 donors. Many members of the AKR1 family have 
been implicated for their role in the carcinogenesis of organs such as the breast and 
endometrium by playing a vital role in progesterone signaling and in turn also regulating the 
estrogen: progesterone balance (Bauman et al. 2004; Ji et al. 2004).  
Various other genes involved in phenomena as diverse as cell cycle control, apoptosis 
and developmental regulation were differentially modulated in different individuals. A 
multitude of genes coding for proteins such as kinases, Ca binding proteins, cell junction 
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proteins, growth factors, G proteins, various receptors, ligands and other regulatory proteins 
involved in various facets of cell signaling were differentially regulated by CHL being ‘up’ 
in some donors and ‘down’ in others thereby indicating that modulatory effects of CHL may 
partly be mediated through modulation of cellular communication processes.  
Various immune response genes were also altered differentially by CHL. Genes such 
as SLP1, a serine protease (Devoogdt et al. 2003), interleukin 8 (Huang et al. 2002; Mian et 
al. 2003), IL1B and several other altered immune response genes have been found to enhance 
the risk of different cancers. Their up-regulation by CHL treatment may be explained as the 
response possibly mediated by the interactive action of BP +CHL together. Interferon alpha 
(IFNA), a gene with the highest degree of up-regulation compared to all other genes (in one 
cell strain M99016) has at times been shown to exhibit antitumor effects (Zella et al. 1999). 
Its differential regulation in the 6 cell strains could be due to polymorphisms in the gene for 
this cytokine or other down stream modulators in the signaling pathway thereby ultimately 
leading to differential expression extents and differential effects. CD80 didn’t exhibit up-
regulation in most of the cell strains except M99016 and has been reported to activate 
cytotoxic T lymphocytes (Chan et al. 2004) and also provide negative signals for the 
proliferation and IgG secretion of normal B cells and B cell lymphomas (Suvas et al. 2002). 
CD86 up-regulated in most of the cell strains has been found to have a role in priming and 
activation of naive and memory T cells, respectively (Jeannin et al. 2000) and also for 
enhanced activity of B cells (Suvas et al. 2002). PI3, protease inhibitor, up-regulated by CHL 
treatment in most of the individuals (except M99005 and M99025) has been reported to have 
a role in cell differentiation and apoptosis (Yamamoto et al. 1997) and possibly in the control 
of tumor cell invasion (Alkemade et al. 1993).  
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A number of other genes with diverse functions, ORF’s and sequences coding for 
hypothetical proteins were differentially modulated by CHL and are presently not very well 
characterized in relation to cancer. However, many of these are involved in several 
developmental processes indicating that developmental processes may also form some key 
targets of attack several by some PAHs.  
Genes down-regulated by the interactive action of BP + CHL included those whose 
enhanced expression has been documented to aid either directly or indirectly the progression 
of various cancers, e.g.:SOD2 (Drane et al. 2001), CRY61 (Lin et al. 2005), RAI3 (Wu et al. 
2005) and several others. However, various other genes whose enhanced expression is 
known to inhibit various facets of carcinogenesis were also down-regulated by the interactive 
action of BP + CHL. These included AFT3 (Yan et al. 2005), OCLN (Tobioka et al. 2004), 
GADD45B (Qiu et al. 2003), ADAMST1 (Iruela-Arispe et al. 2003), MEST1 (Pedersen et al. 
1999) and DOC1 (Schwarze et al. 2002).  
Nine genes with a role in immune responses were down- regulated by BP + CHL.  Of 
these, some like the interferon alpha inducible protein (IFI27) down-regulated in all 6 cell 
strains, is a protein suggested to be a novel biomarker of epithelial proliferation and cancer 
(Suomela et al. 2004). GIP2 (INSIG1) consistently down-regulated in all the cell strains has 
previously been suggested to function intracellularly as a ubiquitin homologue and a 
cytokine that induces production of IFN-gamma to augment NK/lymphokine-activated killer 
cell proliferation and function, possibly playing a vital role in antiviral response (Zhao et al. 
2005). CXCL2 has been implicated in inflammatory responses along with other chemokines 
and cytokines (Yamagami et al. 2003) in human corneal endothelium and human melanoma 
cells (Gallagher et al. 2005).  
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Not much is known about the role of the remaining genes in relation to cancer and 
disease.  
 
5.2 Correlation of gene expression on microarrays versus RT-PCR 
Overall, there was a good correlation between the magnitude of expression for 
different genes as measured by GC and by RT-PCR. However, there were a few genes which 
correlated only moderately to poorly. In general, RT-PCR was more sensitive than GC in 
measuring gene expression changes. The lack of good correlation for some genes may be due 
to the comparatively lower sensitivity of GC in relation to RT-PCR in addition to differences 
in the exact regions being probed by GC and RT-PCR. A low level of expression of 
particular gene in only some individuals may cause GC to ‘miss’ it or at most exhibit its 
expression at an extremely low level, whereas RT-PCR being more sensitive may be able to 
more realistically track its expression giving a higher FC compared to GC culminating in a 
poor correlation.   
CHL clearly appears to be a ‘bifunctional inducer’ modulating the expression of both 
bioactivating and detoxication enzymes. Various other functional categories of genes 
modulated by the interactive action of BP + CHL may point to various other presently 
unknown targets and mechanisms of action of CHL though these will need to be confirmed. 
Some genes (AKR1C1, SECTM1, CRY61 and a few others) following a similar trend of 
modulation in most donors though not necessarily by SLR≥ 1.5 in all of them suggest that 
these could be good putative ‘biomarkers of exposure’ to be confirmed by further validation. 
Many other genes not consistently altered in a similar direction across all donors suggest the 
presence of extensive inter-individual variability in response to carcinogenic stress and 
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intervention strategies, an issue addressed earlier in our laboratory regarding CYP1A1 and 
CYP1B1 (John et al.). However, despite inter-individual differences, CYP1B1 followed by 
ALDH1A3 were consistently up-regulated in most individuals following treatment with BP as 
well as BP + CHL indicating that these could be definite biomarkers of BP exposure. The 
consistent up-regulation of CYP1B1 by BP has been previously reported from our laboratory 
(Keshava et al. 2005) and was further confirmed by RT-PCR studies of the 20 NHMEC 
strains as discussed below. 
 
5.3 Genetic damage in terms of CYP1 induction and DNA adduct formation in 20 
NHMECs on treatment with BP in the absence or presence of CHL 
PAHs, including BP, are known to bring about their own metabolism through the Ahr 
pathway (Ma et al. 2003). CYP1A1, a substrate inducible enzyme expressed predominantly 
in extra hepatic tissues including the breast (Whitlock 1999; Masson et al. 2005) was highly 
induced in our studies ( 96 fold variation). Its induction, however, correlated poorly with 
donor age. This is in agreement with another study which also found an age independent 
variation in the expression of CYP1A1 in normal breast tissue samples (n =58) obtained from 
breast cancer patients and normal cancer free individuals (Goth-Goldstein et al. 2000). The 
induction of CYP1B1 was much less (43 fold variation) as compared to CYP1A1 and also 
correlated poorly with the age of the donor. In contrast to CYP1A1, CYP1B1 is expressed 
constitutively in various extra hepatic tissues including the breast but exhibits weak induction 
by Ahr ligands which may explain its lower induction in our study compared to CYP1A1 (Ma 
et al. 2003).  
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The wide inter-individual differences among the cell strains in the induction of both 
CYP1A1 and CYP1B1 could be explained at least in part due to polymorphisms in the genes 
coding for CYPs and other Phase I enzymes, AhR-Arnt as well as detoxication and repair 
enzymes (Ma et al. 2003; Weston et al. 2005). In addition, physiological factors (such as the 
presence of endogenous agonists or antagonists), environmental and dietary exposures of the 
donors could also play a role although these are much less likely, since the cells have been in 
culture for long. Given the fact that majority of the cell strains were of Caucasian origin, 
variability due to ethnic differences though low cannot be ruled out completely. The presence 
of only a moderate to poor correlation between the induction of both CYP1A1 and CYP1B1 
both in the absence and presence of CHL may suggest that both of these isoforms could be 
differentially regulated in response to BP or the fact that one isoform may be involved to a 
greater extent in carcinogen metabolism than the other or both. In fact, CYP1B1 has been 
found to be catalytically more active than CYP1A1 in the bioactivation of different PAHs 
(Shimada et al. 1996).  
The universal reduction in the induction of both CYP1A1 and CYP1B1 in all the cell 
strains upon co-treatment as well as the existence of a good correlation between the fold 
induction upon treatment with BP alone and upon co-treatment (when CHL is present along 
with the carcinogen) suggests the action of CHL as an ‘interceptor molecule,’ reducing the 
availability of BP to trigger the Ahr pathway. Other in vivo studies have also found highly 
effective inhibition when CHL was co-administered with the carcinogen (Dashwood 1997a). 
A reduction in CYP1 expression in most individuals upon treatment with CHL prior to 
carcinogen exposure (pre CHL + post BP) suggests mitigation of CYP1 expression by 
mechanisms other than just carcinogen sequestration. Prior exposure to CHL may in some 
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manner alter specific cell signaling circuitry or modulate the abundance of Phase I enzymes 
directly or indirectly by altering the genes/proteins involved in the ‘Ahr’ battery.’ This 
however, might not be a universal phenomenon and the ‘bifunctional’ nature of CHL may be 
coming into play to different extents in different individuals which might in part explain the 
increase in CYP1 expression in some individuals upon CHL pretreatment. However, the 
exact molecular mechanism of CHL mediated modulation of CYP1 gene expression upon its 
administration prior to carcinogen exposure is currently unknown. Pre CHL treatment 
followed by co-treatment enables CHL to act both as a chelator and as a modulator of CYP1 
gene expression thereby causing a reduction in CYP1 expression in the majority of 
individuals and also causing a greater reduction in expression compared to other CHL 
treatments where CHL acts predominantly by any one of the above mechanisms. This is 
exemplified by the presence of a good correlation between the percentage reduction in the 
expression of CYP1A1 to CYP1B1 upon pre-treatment with CHL followed by co-treatment in 
the absence of outliers. 
The reduction in adduct levels in most of the cell strains on co-treatment again points 
to the role of CHL as an ‘interceptor’ molecule sequestering the carcinogen and preventing it 
from interacting with DNA. This mechanism, however, requires CHL to be present in large 
molar excess compared to the carcinogen (Dashwood 1997a). Non-specific inhibition of 
CYPs may also lead to reduced metabolism of the carcinogen in turn leading to reduced 
availability of the carcinogen to interact with DNA as in a pre CHL + post BP treatment. 
However, the poor correlation between CYP1 expression and DNA-adduct levels may 
suggest interplay of Ahr independent mechanisms of activation along with cross-talks with 
various other cellular pathways and/or factors. Aldo keto reductases (AKRs) have also been 
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shown to have a role in the metabolism of BP. In this respect, human AKR1A1, AKR1C1–
AKR1C4 have been found to be particularly active in metabolizing BP to reactive quinone 
metabolites and also generating of reactive oxygen species. AKR1A1 has been found to 
serve a dual role in directly metabolizing the BP-7,8-diols to reactive quinones and also 
indirectly trans-activating CYP1B1 (Jiang et al. 2004). A peroxidase pathway for BP 
metabolism is also documented to exist (Cavalieri et al. 1995). Though there are hardly any 
studies on the role of flavin monooxygenases in BP metabolism it may not be misleading to 
assume that these monooxygenases along with various other Phase I enzymes may 
potentially play at least a minor role in the metabolism of BP in some individuals. Many of 
these processes compete with the CYP pathway for BP metabolism. In addition, basal 
expression along with induced CYPs is responsible for metabolism of the compound to toxic 
metabolites. Therefore, trying to correlate only induced expression with the extent of BP-
DNA adducts may give poor correlation. The basal expression levels in terms of RNA copy 
number need to be determined in future studies. Also, should CHL be triggering Phase II 
metabolic reactions (Fahey et al. 2005) or DNA repair process some of the reactive 
metabolites/ adducts formed may either be prevented from interacting with DNA or repaired, 
respectively leading to the lack of a good correlation. 
 
5.4 Genetic damage in terms of CYP1 induction and DNA adduct formation in 2 
NHMECs on treatment with BP or B[e]P in the absence or presence of CHL 
With respect to the studies on comparison of BP versus B[e]P, the lower potency of 
B[e]P in inducing CYPs and forming adducts was apparent. BP is a strong PAH receptor 
(8S) ligand but a weak PAH-binding protein (4S) ligand whereas B[e]P is mainly a 4S ligand 
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but a poor AH receptor ligand (Houser et al. 1992; Sterling et al. 1994). This explains the 
overall poor induction of CYP1 by B[e]P compared to BP in both cell strains. However, an 
explanation for the differential action of CHL towards B[e]P induced CYP1 expression is 
unknown. The enhancement in CYP1 expression in most cases involving a co-treatment of 
CHL with the carcinogen may suggest a lack of efficient complex formation between B[e]P 
and CHL probably due to some change in carcinogen structure and subsequent alteration of 
stabilizing forces. In fact CHL has been found to form tight molecular complexes with planar 
aromatic hydrocarbons possessing at least partial ring structure when present in large molar 
excess to the carcinogen and administered simultaneously with the carcinogen (Dashwood 
1997a). CHL in low concentrations has been shown to have the potential to act as an 
NADPH generating system by replacing glucose 6-phosphate (Waters et al. 1996). This was 
a mechanism suggested for the ‘potentiator effect’ of low concentration of CHL against 
nitrosamines (Waters et al. 1996) which was, however, reversed at higher CHL 
concentrations. Here, though the concentration of CHL used for intervention of BP and B[e]P 
was the same, in the absence of effective complex formation as in the case of B[e]P, the low 
concentration of free CHL may have the potential to bring about ‘potentiation’ through the 
above mechanism. This suggests that though some carcinogens may be only weakly 
carcinogenic they may be rendered more active in the presence of certain chemopreventive 
agents which are generally administered to mitigate the ill effects of more potent carcinogens 
depending on the concentration and treatment protocol involved. The mechanisms of BP-
DNA adduct reduction by CHL may occur through some of the above discussed 
mechanisms. However, the lack of any detectable adducts by B[e]P in the absence or 
presence of CHL, suggests that there may be a very low level of B[e]P-DNA adducts given 
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its much lower carcinogenicity compared to BP. In addition, synchronous fluorescence 
spectrometry (SFS) may not be sensitive enough to detect rather low levels of adducts 
formed by B[e]P (detection limit of 1 in 107 adducts). A more sensitive assay will be needed 
to detect these low levels of adducts. The presence of a good correlation between CYP1 gene 
expression and BP-DNA adduct formation in M98025 but only a moderate to poor 
correlation in M98015 again points to wide inter-individual variation in induction and 
response to intervention.  
 
5.5 Genetic damage in terms of CYP1 induction and DNA adduct formation in MCF-7 
cells versus an NHMEC (M00012) on treatment with BP or B[e]P in the absence or 
presence of CHL 
Cancerous cells are often used to study various aspects of carcinogenesis. Their 
relative ease of maintenance and faster generation time are some factors which favor their 
use. Here, MCF-7, an estrogen receptor positive breast cancer cell line used in comparison 
with normal breast cells exhibited a response pattern sharply different from those of normal 
cells. CHL failed to mitigate BP induced CYP1 expression and DNA adduct across a range of 
CHL treatments and CHL concentrations suggesting that CHL neither behaves as a CYP 
inhibitor nor an interceptor molecule in these cells. However, it remains to be determined 
whether this is an exclusive response exhibited by MCF-7 cells or is commonly exhibited by 
other cancerous cells including other breast cancer cells, some of which may be estrogen 
receptor negative. Though the induction of CYP1B1 was low compared to CYP1A1 its basal 
expression was much higher than that of CYP1A1. This has been shown even in a few other 
studies (McKay et al. 1995; Spink et al. 1998). Nevertheless, it shows that cancerous cells 
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exhibit different response patterns compared to normal cells and therefore cannot be used  as 
surrogates to predict responses of normal cells to carcinogens and chemopreventive agents.  
 BP is a widely distributed environmental carcinogen and a high risk factor for a 
large section of the world’s population whose dietary lifestyle involves use of tobacco. 
Smoking alone has been linked to about 30% of all cancer deaths and more than 400,000 
premature deaths/year in the U.S. alone (http://www.cancer.org/docroot/PED/ped_10.asp; 
http://www.cdc.gov/HealthyYouth/tobacco). A greater understanding of the ‘molecular 
changes’ that ensue following PAH exposure can help better design exposure monitoring and 
intervention strategies. This study has revealed at least a few potential biomarkers of 
exposure some of which could be potential targets for intervention strategies. Clearly, 
CYP1B1 is one such target as seen from this study. Additionally, CHL appears to function as 
a bifunctional inducer differentially modulating the expression of most genes except a few 
where most individuals seem to respond in a similar fashion. Wide inter-individual variations 
will need to be accounted for during biomarker validation as well as while designing 
intervention strategies.  
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6.0 SUMMARY AND CONCLUSIONS 
 
These studies were intended to extend our understanding of human chemical 
carcinogenesis, potential biomarkers of carcinogen exposure and strategies for 
chemoprevention. To do this a human mammary cell model system was exposed in vitro to 
benzo[a]pyrene a known polycyclic aromatic hydrocarbon carcinogen, with or without 
chlorophyllin, a potential chemopreventive agent. The effects of these exposures on gene 
expression and carcinogenesis precursor events were evaluated. 
Global gene expression analysis was carried out to seek for biomarkers of carcinogen 
exposure and chemopreventive intervention. Immune response genes altered on exposure to 
polycyclic aromatic hydrocarbons, with or without the modulating agent, chlorophyllin, were 
analyzed in the context of having cross-talks between themselves as well as interacting with 
several other cellular pathways.  The expression of cytochrome P450 (CYP1) enzymes 
involved in polycyclic aromatic hydrocarbon metabolism was examined across a spectrum of 
individuals in relation to their ability to cause DNA damage, in the absence and presence of 
chlorophyllin. 
CYP1B1 appeared to be a potential biomarker of polycyclic aromatic hydrocarbon 
exposure.  Chlorophyllin served as an effective chemopreventive agent in mitigating genetic 
damage by reducing polycyclic aromatic hydrocarbon metabolism and the extent of DNA 
damage. 
The main conclusions from the study are that: 
• Genes from a broad spectrum of functional categories were altered by exposure to BP 
in the absence or presence of chlorophyllin.  
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• Only CYP1B1 was altered in a consistent manner across all donors, and therefore 
appeared to be good biomarker of polycyclic aromatic hydrocarbon exposure and 
chemopreventive intervention. All other genes were altered in a less consistent in one 
or more donors indicating inter-individual variations in responses. 
• Extensive inter-individual variations were observed in the extent of induction and 
modulation of CYP1A1 and CYP1B1 expression as well as benzo[a]pyrene-DNA 
adduct formation on exposure to benzo[a]pyrene in the absence or presence of 
chlorophyllin. 
• The reduction of CYP1 gene expression and BP-DNA adduct formation in most normal 
human mammary epithelial cells suggests the role of chlorophyllin acts as a 
‘cytochrome P450 inhibitor’ as well as a ‘chelator’ in mitigating genetic damage. 
• Chlorophyllin may enhance the carcinogenicity of even weakly carcinogenic 
polycyclic aromatic hydrocarbons. The extent of enhancement depends on the nature of 
the carcinogen as well as the time of chlorophyllin administration as seen from the 
enhancement of benzo[e]pyrene induced  CYP1 gene expression  by pre chlorophyllin 
+ post benzo[e]pyrene treatment but not  any of the other chlorophyllin treatments. 
• Cancerous MCF-7 cells exhibited high levels of CYP1A1 induction and 
benzo[a]pyrene-DNA adduct formation on exposure to benzo[a]pyrene, both in the 
absence and presence of chlorophyllin, suggesting probably a different mechanism of 
chlorophyllin action in cancerous cell as opposed to normal cells and/or the fact that 
MCF-7 may be an inappropriate surrogate to normal mammary cells. 
• Only chlorophyllin concentrations higher than those used in other experiments (8 μM, 
16 µM) mitigated BP induced CYP1 gene expression in MCF-7 cells. However, none 
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of the chlorophyllin concentrations mitigated BP-DNA adduct formation in MCF-7 
cells supporting the previous conclusion. 
• The lack of reduction in the extent of CYP1 gene expression and benzo[a]pyrene-DNA 
adduct formation in MCF-7 cells suggests that chlorophyllin performs poorly as a 
‘CYP inhibitor’ and ‘chelator’ in MCF-7 cells. 
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7.0 FUTURE DIRECTIONS 
 
• In order to gain a better understanding of the correlation between CYP1 gene 
expression and BP-DNA adduct formation an assessment of gene copy number needs 
to be determined. This will also help reveal the possible interplay of Ahr independent 
mechanisms in the metabolism of BP. 
• The balance between toxicity and detoxication can be better understood if the effects of 
CHL on other phase I enzymes, e.g., other monooxygenases, in addition to the phase II 
enzyme battery are determined. 
• The effect of chlorophyllin alone on global gene expression would be a valuable asset 
to the scientific community involved in screening for new cancer chemopreventive 
agents. 
• Studies on functional CYP1 enzyme abundance and activity following exposure of 
cells to BP in the absence or presence of CHL will help reveal whether CHL mediated 
changes are transcriptionally or translationally regulated and in turn will help gain a 
better understanding of the mechanistic aspects of CHL action and BP metabolism. 
• Studies on a wider spectrum of cancerous cells will help determine whether the large 
extent of genetic damage as seen in MCF-7 cells (as opposed to NHMECs) is a 
common feature of most cancerous cells and in turn point to the feasibility of using 
cancerous cells as surrogates to normal cells for studying the carcinogenic process. 
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9.0 APPENDIX 
 
Tissue Mix media 
Penicillin Streptomycin mix (10,000U/ml Penicillin G sodium and  
10,000U/ml Streptomycin sulfate)       10 ml 
Fungizone (250μg/ml Amphothericin and 250μg/ml sodium deoxycholate)  20 ml 
Insulin (10mg/ml)         1 ml 
Hanks buffered saline         969 ml 
Total                      1000 ml
  
Filter through 0.2μM filter. 
 
Tissue Digestion media 
Tissue mix media         70 ml 
Collagenase (2000U/ml)        10 ml 
Hyaluronidase          10 ml 
Fetal Bovine Serum         10 ml 
Total                                  100 ml 
Filter through 0.2μM filter. 
  
   
Freezing media 
MEBM media          80 ml 
DMSO           10 ml 
Fetal Bovine Serum         10 ml 
Total           100 ml 
Filter through 0.2μM filter.  
          
 
MCF-7 media 
DMEM (Dulbecco’s modified Eagle’s medium)             894.5 ml 
Fetal calf serum (FCS)*        100 ml 
Penicillin (5000U/ml)-Streptomycin mix (5000μg/ml) mix        2 ml 
Amphothericin B (250μg/ml)            1 ml 
Insulin (1000 μg/ml)                     2.5 ml 
Total                    1000 ml  
Filter through 0.2μM filter. 
* FCS is to be heated (560C for 50 min) to inactivate components of the  
complement system 
  
      
5X RNA Fragmentation buffer 
200 mM Tris acetate, pH 8.1 
500 mM potassium acetate 
150 mM magnesium acetate 
